•



### Aug 28, 2020

# mariPOC User manual.5.5.20

vincent.degennaro 1

<sup>1</sup>ArcDia

1 Works for me

This document is published without a DOI.

API Pharma LLC

vincent.degennaro

DOCUMENT CITATION

vincent.degennaro 2020. mariPOC User manual.5.5.20. **protocols.io** https://protocols.io/view/maripoc-user-manual-5-5-20-bkfrktm6

LICENSE

This is an open access document distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited

CREATED

Aug 28, 2020

LAST MODIFIED

Aug 28, 2020

DOCUMENT INTEGER ID

41169

#### DISCLAIMER:

## DISCLAIMER - FOR INFORMATIONAL PURPOSES ONLY; USE AT YOUR OWN RISK

The protocol content here is for informational purposes only and does not constitute legal, medical, clinical, or safety advice, or otherwise; content added to <a href="protocols.io">protocols.io</a> is not peer reviewed and may not have undergone a formal approval of any kind. Information presented in this protocol should not substitute for independent professional judgment, advice, diagnosis, or treatment. Any action you take or refrain from taking using or relying upon the information presented here is strictly at your own risk. You agree that neither the Company nor any of the authors, contributors, administrators, or anyone else associated with <a href="protocols.io">protocols.io</a>, can be held responsible for your use of the information contained in or linked to this protocol or any of our Sites/Apps and Services.

mariPOC® RTI combi+ test plate mariPOC® RTI combi test plate mariPOC® Respi+ test plate mariPOC® Respi test plate mariPOC® Pharyn test plate mariPOC® Quick combi+ test plate

#### **USER'S MANUAL**

mariPOC® Quick combi test plate mariPOC® Gastro test plate mariPOC® Gastro CDI combi test plate mariPOC® Analyser AD7-020 mariPOC® Software (ArcDiagnoser™ version 20.01 or later)

mariPOC® is an automated multianalyte rapid test system for detection of acute infection pathogens from patientsamples mariPOC® test plates are intended for use together with the computer controlled mariPOC® analyser

New samples can be added to the mariPOC® test system while the analysis of the previous samples is still in progress (i.e., so-called random accessoperation)

mariPOC@+ mode of the measuring program is intended primarily for laboratories. It enables result interpretation and use of multiple test plates on the same analyser.

ble of contents		

Intended Use 4
1.1mariPOC® Respi+, Respi and Pharyn Tests 4
1.2mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA Tests 5
1.3mariPOC® SARS-CoV-2 Test 5
1.4mariPOC® Gastro and CDI Tests 5
2
Test System Features 7
2.1 Test System Order Details 7
2.2Description of Test System Components 14
3
Precautions and Safety Instructions 16
4
Operating Conditions, Storage and Maintenance 17
5
Test Dringinle 20
Test Principle 20
6
Test Performance 21
6.1mariPOC®Respi+,Respi,SARS-CoV-2,Pharyn,QuickFlu+,QuickFlu/RSVandQuickStrepATests 21
6.2mariPOC® Gastro and CDI Tests 28
7
<u>Using the Test System 32</u>
7.1 <u>Deployment of the Test System 32</u>
7.2mariPOC® Software (ArcDiagnoser™ Measuring Program) 32
7.3 <u>Performing the Test and Reading the Results 37</u>
7.3.1 <u>Sampling 37</u>
7.3.2 <u>Storage of Samples 38</u>
7.3.3Respi+, Respi, Respi < 7 Years Old, Quick Flu+, Quick Flu/RSV and SARS-CoV-2 Tests 38
7.3.4 <u>Pharyn and Quick StrepA Tests 45</u>
7.3.5Gastro andCDITests49
7.3.6 <u>Reading and Reporting of the Results 55</u>
7.4 <u>Control Samples 61</u>
7.5Running Out of Tests and Changing the Test Plate 63
7.6 Changing and Emptying the Solution Containers 65
7.7 <u>Creating Customer Support Report 67</u>
7.7 <u>Creating Customer Support Report 67</u>
7.7 <u>Creating Customer Support Report 67</u> 7.8 <u>Switching the Analyser Off and On 67</u>

Cleaning and Waste Disposal 69

9

Remarks 70 10	
Possible Problem Situations and Potential Solutions 72  10.1When to Contact Customer Support 72  10.2Problems when Using the Test System 72  10.3Problems with Results 76  11	
Test System Technical Data 81 12	
Symbols Description 82 13	
Warranty 83 14	
<u>Literature 84</u> 15	

#### Manufacturer's Contact Details 86

## 1 Intended Use

The mariPOC® test system is designed to be used for detection of pathogens from patients with acuteinfections. ThemariPOC® testsystemenables the analysis of different pathogen combinations from patients amples (Figure 1, Figure 2 and Figure 3). The combination is selected according to the clinical picture, clinical symptoms, and the age of the patient if appropriate. The product is intended for invitro diagnostic professional use. Test system equipped with mari POC® + measuring program is intended primarily for laboratories.

The manufacturer or manufacturer's representative will familiarise the user organisation with the testsystem.

#### 1.1 mariPOC® Respi+, Respi and Pharyn Tests

ThemultianalytemariPOC®Respi+,RespiandPharyntestsaredesignedtobeusedfordetection of acute respiratory tract infection pathogens from nasopharyngeal or throat samples depending on the test (Figure 1). Sampling for the detection of viral pathogens should be done during viremia within 6 days from the onset of symptoms, preferably within 5 days. Viral loads decrease over time and virus antigens are not usually detectable after 6 to 7 days from the onset of symptoms.

The Pharyn test is intended to be used when there is clinical suspicion of pharyngitis. The group A streptococci method of the Pharyn test can be used for the detection of the pathogen in perianal streptococcal dermatitis. The Respi+ and Respi tests are intended to be used for other lower and upperrespiratorytractinfections.IntheRespi+andRespitests,theanalytestobetesteddependon the patient's age. Pneumococcus is not measured in small children due to the high frequency of asymptomatic carriers (the Respi < 7 years old test). Test selection is patient-specific and is made with the measuringprogram.

Depending on the indication, the sample is collected either from the nasopharynx using a swab, aspirate or wash procedures, or from the pharynx or the perianal area using a swab procedure. Suitable flocked swabs are defined in **Table 7**. **Figure 1.** Pathogens covered by the mariPOC® Respi+, Respi and Pharyn tests.

1.2 mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA Tests

The mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA (**Figure 2**) rapid tests are intended to be used for the detection of acute

The mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA (Figure 2) rapid tests are intended to be used for the detection of acute respiratory tract infection pathogens. The mariPOC® Quick Flu/RSV test detects influenza A and B viruses and respiratory syncytial virus and in addition to these the mariPOC® Quick Flu+ detects SARS coronavirus 2 from nasopharyngeal samples in 20 minutes. ThemariPOC®QuickStrepAtestdetectsgroupAstreptococcifromthroatsamplein15minutes. The

 $\label{thm:pathogeninper} Quick Strep A test may be used for the detection of the pathogen in perianal strep to coccal dermatitis.$ 

Sample collection is similar to Respi and Pharyn tests. The Quick tests can be selected from Combi+ and Combi tests plate (<u>Table</u> only if the Quick feature is enabled in the measuring program.

Figure 2. Pathogens covered by the mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA tests.

#### 1.3 mariPOC® SARS-CoV-2 Test

The mariPOC® SARS-CoV-2 test is intended to be used for the detection of the virus when there is a clinical suspicion of acute coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The SARS-CoV-2 test detects SARS-CoV-1 and SARS-CoV-2. The sample collection is similar to Respitest.

#### 1.4 mariPOC® Gastro and CDI Tests

The mariPOC® Gastro and CDI tests (**Figure 3**) are intended to be used for the detection of pathogens, causing gastroenteritis, from stool samples. The samples should be obtained from patients with symptoms of acute gastrointestinal infection, e.g. diarrhoea and/or vomiting.

Sampling for the detection of viral pathogens from a stool sample should be done within few days from the onset of symptoms. Viral loads decrease over time and virus antigens are not usually

detectableafteraweek.Bacteriaaremoreprobablefindingsthanvirusesfromastoolsampleswhen the symptoms are prolonged. The Gastro test enables the analysis of five different pathogens that cause similar symptoms at the onset of the gastrointestinal infection. The CDI test is intended to be used mainly when there is clinical suspicion of *Clostridium difficile* infection (CDI). The CDI test enables the analysis of CDI by detecting the presence of *C. difficile* GDH (*C. difficile* specific surface protein glutamate dehydrogenase) and *C. difficile* toxins A and B.

Figure 3. Pathogens and/or analytes covered by the mariPOC® Gastro and CDI tests.

### 2 Test System Features

#### 2.1 Test System Order Details

The mariPOC® test system consists of an analyser package (<u>Table 1</u>) and consumables (<u>Table 2</u> and <u>Table 3</u>)

Table 1. The content of the analyser package.

REF	Product name
AD7-020	mariPOC® Analyser
A-21	Analyser power supply
A-22	Computer
A-9	Waste container (2.5 L)
A-12	Label printer
A-14	Bottletop dispenser (dispensing volume 1.3 ml)
A-29	Bottletop dispenser stand
A-16	Vortex mixer (minimum speed 2700 rpm and orbit 6
	mm)
A-18	Sample tube rack
A-30	Sample tube box
A-31	Sample tube cap box
A-33	USB flash drive
A-36	2 Ethernet cables
A-37	Ethernet switch
A-28	Uninterruptible power supply (UPS), optional
A-43	Test plate storage rack
AD1-S	mariPOC® Software (ArcDiagnoser™ measuring
	program)
-	User's manual
-	Rapid instructions
-	Safety data sheets (SDS)

 $\textbf{Table 2.} Test system consumable 's product numbers (REF), names and package sizes. If a consumable is marked with X, it is necessary to order with that mariPOC {\tt @test plate} product for respiratory tract in fections.$ 

REF	Product name and package size	1194M mariP OC® RTI combi+ test plate	1164M mariP OC® RTI combi test plate	1184M mariP OC® Respi+ test plate	1154M mariP OC® Respi test plate	1124M mariP OC® Pharyn test plate	1214M mariP OC® Quick combi + test plate	1174M mariP OC® Quick combi test plate	1204S mariP OC® SARS- CoV-2 test plate
1104MC	mariPOC® RTI control samples (includes 1 negative and 1 positive control sample)	х	Х	X	Х	Х	Х	Х	
1124MC	mariPOC® Pharyn control samples (includes 1 negative and 1 positive control sample)					Х			

1204SC	mariPOC® SARS-2 control samples (includes 1 negative and 1 positive sample)								x
B02	mariPOC® RTI sample buffer (0.5 L)	X	X	X	X	X	X	X	X
B03A	mariPOC® Extraction solution A for Pharyn and Quick StrepA tests (15 ml)	X	X			Х	X	X	
B03B	mariPOC® Extraction solution B for Pharyn and Quick StrepA tests (15 ml)	X	X			X	X	X	
B04	mariPOC® Wash solution (2.0 L)	Х	Χ	X	Χ	X	Χ	X	Х
B05	mariPOC® System solution (1.0 L)	X	X	X	X	X	X	X	X
A-1	mariPOC® Sample tubes (100 pcs)	X	X	X	X	X	Χ	X	X
A-2	mariPOC® Sample tube caps (100 pcs)	X	X	X	X	X	X	X	X
A-13	Label tape (1 pcs)	Χ	Χ	Χ	Χ	Χ	Χ	Χ	Χ

Table 3. Test system consumable 's product numbers (REF), names and package sizes. If a consumable is marked with X, it is necessary to order with that mariPOC® test plate product for gastroint estimal infections.

		2017M mariPOC® Gastro test plate	2027M mariPOC® Gastro CDI combi test plate	2037M mariPOC® CDI test plate
REF	Product name and package size			
	mariPOC® Gastro control			
2017MC	samples (includes 1 negative and 1 positive control sample)	X	X	Χ
B04	mariPOC® Wash solution (2.0 L)	Х	Х	Χ
B05	mariPOC® System solution (1.0 L)	X	Χ	Χ
B06	mariPOC® Gastro sample buffer (0.5 L)	Х	X	Χ
A-1	mariPOC® Sample tubes (100 pcs)	X	X	X
A-2	mariPOC® Sample tube caps (100 pcs)	X	Х	Χ
A-13	Label tape (1 pcs)	X	Χ	Χ
A-45	Syringe (5 ml, 100 pcs)	Х	Χ	Χ
A-46	Filter (150 pcs)	Χ	X	X

A-47	Pasteur pipette (250 pcs), optional	X	X	Χ
A-48	Swab in transport tube (100 pcs)	Χ	Χ	Χ

See more information about mariPOC® test plates in <u>Table 4</u>, <u>Table 5</u> and <u>Table 6</u>.

Table 4. mariPOC® test plates and amount of tests in them.

REF	Test plate name	Test type	Tests/plate
		Respi+,	22
1194M	mariPOC® RTI combi+ test plate	Quick Flu+ or Quick Flu/RSV Pharyn or Quick StrepA	22
		Respi or	22
1164M	mariPOC® RTI combi test plate	Quick Flu/RSV Pharyn or Quick StrepA	22
1184M	mariPOC® Respi+ test plate	Respi+, Quick Flu+ or Quick Flu/RSV	22
1154M	mariPOC® Respi test plate	Respi or Quick Flu/RSV	22
1124M	mariPOC® Pharyn test plate	Pharyn or Quick StrepA	66
		Quick Flu+	22
1214M	mariPOC® Quick combi+ test plate	Quick StrepA	22
		Quick	22
1174M	mariPOC® Quick combi test plate	Flu/RSV Quick StrepA	22
1204S	mariPOC® SARS-CoV-2 test plate	SARS-CoV-2	308
2017M	mariPOC® Gastro test plate	Gastro	44
		Gastro	44
2027M	mariPOC® Gastro CDI combi test plate	CDI	44
2037M	mariPOC® CDI test plate	CDI	44

**Table 5.** Target pathogen coverage of the mariPOC® test plates for respiratory tract infections. **mariPOC® test plate name and REF** 

Test type and pathogen coverage	RTI combi+	RTI combi	Respi+	Respi	Pharyn	Quick combi+	Quick combi	SARS- CoV-2	
1194M	1164M	1184M	1154M	1124M	1214M	1174M	1204S		
Respi+, Respi, Quick Flu+, Quick Flu/RSV or SARS-CoV-2	Influenza A virus	+	+	+	+	-	+	+	-
Influenza B virus	+	+	+	+	-	+	+	-	
Respiratory syncytial virus	+	+	+	+	-	+	+	-	
Human metapneumovirus	+	+	+	+	-	-	-	-	
Human bocavirus	-	+	-	+	-	-	-	-	
SARS coronavirus 2	+	-	+	-	-	+	-	+	
Human coronavirus OC43	+	+	+	+	-	-	-	-	
Parainfluenza 1 virus	+	+	+	+	-	-	-	-	

Parainfluenza 2 virus	+	+	+	+	-	-	-	-	
Parainfluenza 3 virus	+	+	+	+	-	-	-	-	
Adenovirus	+	+	+	+	-	-	-	-	
S. pneumoniae	+	+	+	+	-	-	-	-	
Pharyn or Quick StrepA	Group A streptoc occi	+	+	-	-	+	+	+	-
Adenovirus	+	+	-	-	+	-	-	-	

**Table 6.** Target pathogen coverage of the mariPOC® test plates for gastrointestinal infection. **mariPOC® test plate name and REF** 

	Gastro 2017M	Gastro CDI	CDI 2037M	
Test type and pathogen		combi 2027M		
coverage				
Gastro	Norovirus GII.4	+	+	-
Norovirus GI	+	+	-	
Rotavirus	+	+	-	
Adenovirus	+	+	-	
Campylobacter spp.	+	+	-	
CDI	C. difficile	-	+	+
	GDH			
C. difficile Toxin A/B	-	+	+	

#### Other mandatory equipment:

Use only flocked swabs for swab sampling. So far Copan flocked swabs are the only ones that have been clinically validated to be used in combination with the mariPOC® Respi+, Respi, Pharyn, Quick Flu+, Quick Flu/RSV and Quick StrepA tests. The following Medical Wire's (Puritan) flocked swabs

 $have been shown to be technically compatible with the mari POC @Respi+, Respi, Pharyn, Quick Flu+, Quick Flu/RSV \ and \ Quick Strep A tests, while their performance in clinical diagnostics has not yet been studied extensively.$ 

Table 7. Recommended flocked swabs for sampling.

Size	Description	Manufacturer	REF
Small	Pediatric flocked swab, nylon tip (shaft break point 100 mm), sterile	Copan	516CS01
	Minitip flocked swab, nylon tip (shaft break point 80 mm), sterile	Copan	501CS01
Medium			

let. aut.			
Flexible			
nasopharyngea	Copan	503CS01	
I			
flocked swab,			
nylon tip (shaft			
break point 100			
mm), sterile			
PurFlock®	Medical Wire	MW812	
Ultra Mini Tip			
Flexible Peel			
Pouch			
PurFlock®	Medical Wire	MW813	
Ultra			
Ultrafine			
Flexible Peel			
Pouch			
	Madical Wire	MW/010	
HydraFlock®	Medical Wire	MW819	
Ultrafine			
Flexible Peel			
Pouch			
	Regular flocked swab,		
	nylon tip (shaft break point 80 mm), sterile	Copan	502CS01
Large			
Regular			
flocked swab,	Copan	519CS01	
nylon tip (shaft	'		
break point 100			
mm), sterile			
Regular			
flocked swab,	Conan	520CS01	
	Copan	520CS01	
nylon tip (shaft			
break point 30			
mm), sterile			
PurFlock®	Medical Wire	MW810	
Ultra Standard			
Tapered Peel			
Pouch			
PurFlock®	Medical Wire	MW811	
Ultra Standard			
Flexible Peel			
Pouch			
HydraFlock®	Medical Wire	MW817	
Standard	THOUSE THE		
Flexible Peel			
Pouch			

When handling a swab sample the following items are required that is not included in the test system:

Scissors

Disinfectant (70% ethanol orsimilar)

The nasopharyngeal aspirate or wash sampling procedures and the sample treatment require part of the following laboratory equipment that is not included in the test system:

Nasopharyngeal aspirate collectionkit

Nasopharyngeal wash collection kit

Pipette and tips (0.3 ml and 0.6 ml dispensingvolume)

Centrifuge (1000 g speed requirement) with a suitable adapter for the sample tubes (diameter 11 mm and height 65mm)

Centrifuge (14000 g speed requirement) and high force centrifugation tubes (minimum volume 1 ml)

Filtrationunitrack(REFA-44, Figure 31) is required when handling as tools ample. Please note, that the stool sample collection container is not included in the mariPOC® Gastro and CDI test consumables.

The test results may be printed with the user's printer if necessary.

2.2 Description of Test System Components
---

Figure 4. Analyser, computer, label printer, bottletop dispenser with stand and other components.

Figure 5. Front view of analyser showing components.

Figure 6. Back view of the analyser.

## 3 Precautions and Safety Instructions

The mariPOC® test system is intended for *in vitro* diagnostic use by health care professionals. The users are advised to carefully read this User's manual to be able to correctly use the mariPOC® test system.

The following cautions are used throughout this User's manual:

- -Safety! For safetyinstructions
- -Note! For other important instructions for the correct use of thedevice

Handle all samples and waste materials as if they were capable of transmitting infectious agents. The detailed waste disposal instructions are described in chapter "8 Cleaning and Waste Disposal".

Detailedsafetyinformationoftheproductsarefoundinseparate,productspecificsafetydatasheets (SDS).

 $The \ test \ system \ uses \ a \ strong \ laser \ light \ (Class \ 1 \ laser \ product \ EN \ 60825-1:2014, Third \ Edition; \ specifications in \ \underline{\textbf{Table}}$ 

8) and mechanical movement for analysing samples. For this reason no foreign

bodiesorbodypartsmaybeinsertedintotheanalyser. Theanalysercasing, other than the testplate hatch and the plate carriage and the sample hatch, must not be opened. User exposure to laser radiation in normal use is negligible. Analyser does not have user serviceable partsinside.

Table 8. Laser radiation characteristics.

Maximum accessible power	< 1.95 mW
Pulse duration	0.5 ns
Emitted wavelength	1064 nm

Figure 7. Laser class label mounted on the back of the analyser.

#### 4 Operating Conditions, Storage and Maintenance

The operating temperature range of <u>the test system</u> is  $+21\pm5$ °C. The expiration dates of the consumables are printed on the packages.


<u>Theanalyser</u>mustbestoredonaflatplatformwiththesampleandtestplatehatchesclosed. The analyser must not be exposed to dust, high temperatures, strong vibrations, strong magneticfields, chemicals or chemical vapours. The analyser heats in kmust not be exposed to dust, high temperatures, strong vibrations, strong magnetic fields, chemicals or chemical vapours. The analyser heats in kmust not be exposed to dust, high temperatures, strong vibrations, strong magnetic fields, chemicals or chemical vapours. The analyser heat sink must not be exposed to dust, high temperatures, strong vibrations, strong magnetic fields, chemicals or chemical vapours. The analyser must not be exposed to dust, high temperatures, strong vibrations, strong magnetic fields, chemical vapours. The analyser heat sink must not be exposed to dust, high temperatures, strong vibrations, strong magnetic fields, chemical vapours. The analyser heat sink must not be exposed to dust, and the strong magnetic fields are the strong magnetic fields and the strong magnetic fields are the strong magnetic fields and the strong magnetic fields are the strong magnetic fields and the strong magnetic fields are the strong magnetic fields and the strong magnetic fields are the strong magnetic fields and the strong magnetic fields are th

isatleast1cmoffreespacearoundtheheatsink.Liquidsmustnotbesprayeddirectlyinside or on the analyser! See the analyser cleaning instructions in chapter 8. The preventative maintenance interval of the analyser is 6 months. Only a person authorized by the manufacturer may carry out installation, maintenance or moving of theanalyser.

The test plate, delivered in a foil bag, must be stored at +2 to +8°C. After the foil bag is

opened, the test platemust immediately be placed in side the analyser. The test plate may be handled only by grasping it on its outer edges, and it must not be placed on a dusty surface. Touching the base of the test plate is strictly prohibited (**Figure 8**)! The test plates used for sample analysis are fully traceable (see chapter "7.3.6 Reading and Reporting of the Results";

"mariPOCresults"). The test plate is valid for 30 days from the opening of the foil bagand its insertion into the analyser. The measuring program will report automatically if the test plate is out-of-date. If the test plate is not stored inside the analyser, it must be placed in a special storage rack (see chapter 7.5). The test plate storage rack must not be exposed to temperatures over 60°C.



#### Figure 8. The right and wrong way to handle the test plate.

 $\underline{\text{The control samples}} \ (\text{comprising one positive and one negative control sample in a foil bag)}$ 

 $must be stored unopened at + 2 to + 8^{\circ} C. Once opened, controls amples must be used within 5 hours. Once diluted in the test specific sample buffer, they must be used within 2 hours. The control samples may be used only once.$ 

#### The RTI sample buffer must be stored at +2 to +25° Candprotected from direct sun light. It is

importanttohandletheRTIsamplebuffercarefullyandavoiddirectskincontact.RTIsample buffer contains less than 0.1% microbicide sodium azide. When dispensing the buffer into a sample tube, care must be taken not to contaminate the dispensing head. For example, the sampletubemustnottouchthedispensingheadofthebottletopdispenser.Useofthebuffer must cease immediately if contamination is suspected, the buffer is cloudy or if there is sediment at the bottom of the bottle. In this case, the bottletop dispenser must be cleaned carefully before introducing a new solution bottle. See the cleaning instructions in chapter 10.3.

The Gastro sample buffer must be stored at +2 to +25°C and protected from direct sunlight. It is important to handle the Gastro sample buffer carefully and avoid direct skin contact. Gastro sample buffer contains less than 0.1% microbicide sodium azide. When dispensing the buffer, care must be taken not to contaminate the dispensing head. For example, the tube containing sample must not touch the dispensing head of the bottletop dispenser. Use

ofthebuffermustceaseimmediatelyifcontaminationissuspected, thebufferiscloudy or if there is sediment at the bottom of the bottle. In this case, the bottletop dispenser must be cleaned carefully before introducing a new solution bottle. See the cleaning instructions in chapter 10.3. Please note, that the Gastro sample buffer may contain small amount of floating floccule that do not sediment at the bottom of the bottle. These floccules do not affect the use of the Gastro samplebuffer.

The Wash solution must be stored at +2 to +25°C. The Wash solution contains harmful substances (alkaline) that may irritate the eyes and skin, and therefore it is important to handleitcarefullyandavoiddirectskincontact. Protective gloves must be used. Special care should be taken that the solution does not come into contact with the eyes. If this occurs, wash them immediately with water and seek medical attention. See safety data sheet for more information.

<u>The System solution</u> must be stored at +2 to +25°C and protected from direct sunlight. It is important to handle the System solution carefully and avoid direct skin contact because it contains microbicide, sodium azide (less than 0.1%). Use protective gloves. See safety data sheet for moreinformation.

<u>The Extractions olutions A and B</u>that are used in the Pharyn and Quick Strep A tests must be stored at +2 to +25°C and protected from direct sunlight. The Extraction solutions are valid for 3 months from the opening of the bottles. The Extraction solution A contains sodium nitrite which is harmful if swallowed. The solution may be irritant, and therefore it is important to handle it carefully and avoid direct skin contact. Use appropriate protective equipment if there is a risk of being exposed to productor spills. Special care should be taken that

the solution does not come into contact with the eyes. If this occurs, wash them immediately with water and seek medical attention. See safety data sheet for more information.

Flockedswab and unused flockedswab intransport tuber must be stored in accordance with the swab manufacturer's instructions.

<u>Plasticconsumables</u>mustbestoredappropriatelytoprotectthemfromdustandwithinthe temperature limits of the test system unless otherwise instructed by theirmanufacturers.

The bottletop dispenser must be checked and calibrated when needed, at least every 3

monthsorinaccordancewiththemanufacturer's instructions. These tvolume is 1.3 ml. The average volume of 10 dosages must be 1.225-1.375 ml. The precision (coefficient of variation; CV) of 10 dosages must be  $\leq 2.0\%$ . The density of RTI and Gastrosam plebuffer is 1.0 g/ml.

The filtration unit rack must be stored within the temperature limits of the test system. Filtration unit rack can be cleaned mechanically by brushing with a detergent solution. The rack can be disinfected with chlorine solution (e.g. 1000 ppm) and/or Ultraviolet C (UV-C) light. Aftercleaning, remember to properly rinsether ack with water or / and 70% ethanol (or similar). Please note, that the filtration unit rack's material does not tolerate temperatures over 60°C such as in dishwasher or autoclave.

#### 5 Test Principle

Performing mariPOC® tests consists of the following steps: sampling, entering the patient's information into the user interface, sample pretreatment, inserting the sample into the analyser,

andautomaticanalysisatoneortwotimepoints. Preliminary results are reported for Respi+, Respi, Gastro and CDI tests at 20 minutes and final results at 2 hours. Preliminary results are reported for SARS-CoV-2 test at 20 minutes and final results at 95 minutes. Preliminary results are reported for Pharyn test at 15 minutes and final results at 55 minutes. Preliminary results of Respi+, Respi and Pharyn tests can be omitted from the start-up settings by the manufacturer or field service. At the preliminary results, the test identifies and reports strong and moderately positive samples. At the

finalresults, the testidentifies and reports low positive samples and negative test results. The results are reported at one time point, including positive and negative results, for Quick StrepA test at 15 minutes and for Quick Flu+ and Quick Flu/RSV tests at 20 minutes. Analyte specific identification reactions are based on specific identification of viral or bacterial antigens with monoclonal or affinity purified polyclonal antibodies (immunometric detection). The fluorescence signal measured by the test system from an analyte specific reaction correlates positively with the antigencontent of the sample. The test system compares the signal received from the test to the cut off values set by the manufacturer for positive test results. Based on this

comparison, the sample is reported as positive (+) or negative (-). For S, p neumoniae apositive result is reported semi-quantitatively as + (very low), ++ (low), +++ (medium), or ++++ (high). For group A streptococci in the Pharyn test a positive result is reported semi-quantitatively as + (very low), ++ (low), or ++++ (high) at 55 minute time point. At 15 minute time point only high positive (+++) results are reported. In Quick Strep Atesta positive (+) or an egative (-) result is reported at 15 minute time point. For detailed guidance, see chapter "7.3.6 Reading and Reporting of the Results".

The test system is equipped with an internal autoverification system, which estimates the technical quality and success of the analysis. If the criteria for a reliable test result are not met, the result is not reported (i.e., the analysis is failed). A failed measurement is indicated in red on the patient informationlist. In this case, the sample can be reanalysed or an ewpatient sample can be collected. Internal test result verification of the measuring program utilizes predetermined parameters. This ensures the reliability of a result.

#### 6TestPerformance

In the mariPOC® test system, several pathogens are measured from one patient sample using separate immunochemical identification reactions. The imprecision of the assay signal (coefficient ofvariation)is5–10%forRespi+,Respi,SARS-CoV-2andPharyntestmethodsand3–22%forGastro and CDI test methods, according to the quantitative tests carried out by themanufacturer.

6.1 mari POC @Respi+, Respi, SARS-CoV-2, Pharyn, QuickFlu+, QuickFlu/RSV and QuickStrep A. Tests and Policy and Policy

**Table 9.** Analytical sensitivities of the mariPOC® Respi+, Respi, SARS-CoV-2 and Pharyn tests for standard samples. Analytical sensitivity marked with a star (\*) depends on the applied reporting sensitivity level (see <u>Table 12</u> and chapter "<u>7.3.6 Reading and Reporting of the Results</u>").

Analyte	Analytical
	sensitivity

Influenza A virus	2 ng/ml purified inactivated virus H1N1 (A/New
	Caledonia/20/99)
Influenza B virus	15 ng/ml purified inactivated virus
	(B/Qingdao/102/91)
Respiratory syncytial virus	200 ng/ml purified inactivated virus
Human metapneumovirus	250 ng/L purified antigen
Human bocavirus	10 ng/ml recombinant antigen
SARS coronavirus 2	2 ng/ml recombinant antigen
Human coronavirus OC43	4 ng/ml recombinant antigen
Parainfluenza 1 virus	150 ng/ml purified inactivated virus (Sendai)
Parainfluenza 2 virus	200 ng/ml (according to the preparation) purified
	inactivated virus
Parainfluenza 3 virus	1000 ng/ml (according to the preparation) purified
	inactivated virus
S.	30 ng/L purified antigen, 400 CFU/ml
pneumoniae	
Adenovirus	10 pM purified antigen
Group A streptococci	*3000-9900 bacteria/ml, 200-600
	CFU/ml

Table 10. Analytical sensitivities of the mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA tests for standard samples.

Analyte	Analytical
	sensitivity
Influenza A virus	11 ng/ml purified inactivated virus H1N1 (A/New
	Caledonia/20/99)
Influenza B virus	130 ng/ml purified inactivated virus
	(B/Qingdao/102/91)
Respiratory syncytial virus	3 μg/ml purified inactivated virus
SARS coronavirus 2	6 ng/ml recombinant antigen
Group A streptococci	9900 bacteria/ml, 600 CFU/ml

**Table 11.** Clinical performance of the mariPOC® Respi+, Respi, SARS-CoV-2 and Pharyn tests compared to laboratory methods. These nsitivities of the tests marked with a star (\*) are defined by antigendilution series in the reference study (TR-FIA). This is because of the low incidence of positive clinical samples for those pathogens. See chapter "14 Literature". Clinical sensitivity marked with two stars (\*\*) depends on the applied reporting sensitivity level (see **Table 12** and chapter "7.3.6 Reading and Reporting of the Results").

Analyte	Sensitivity	Specificity	N	Reference
				test
Influenza A virus	92.3%	99.8%	899	PCR
Influenza B virus	88%	100%	192	PCR
Respiratory syncytial virus	89%	100%	158	PCR
Human metapneumovirus	78%	100%	74	PCR
Human bocavirus	76.5%	100%	632	mRNA PCR
SARS coronavirus 2	88%	100%	134	PCR
Human coronavirus 0C43	NA	99.4%	160	PCR
Parainfluenza 1 virus	Similar*	100%	55	TR-FIA
Parainfluenza 2 virus	Similar*	99%	55	TR-FIA
Parainfluenza 3 virus	Similar*	100%	55	TR-FIA
S.	Similar	No cross-reactions	NA	Binax Now® rapid test
pneumoniae				

Adenovirus	92%	100%	95	TR-FIA	
Group A streptococci	100-150%	~100%	328	Culture	

The analytical specificity of mariPOC® multianalyte tests in preliminary result reporting phase is  $\geq$ 99.977% compared to final results.

Table 12. Results reported for group A streptococci in the Pharyn test and corresponding clinical sensitivities compared to culture.

Results	Wording	Explanation	Sensitivity compared to culture
+++	High positive	Likely culture positive	~100%
++	Low positive	Likely culture negative	~120%
+	Very low positive	Very likely culture negative but analytically true positive	~150%

**Table 13.** Clinical performance of the mariPOC® Quick Flu+, Quick Flu/RSV and Quick StrepA tests compared to other laboratory methods.

Analyte	Sensitivity	Specificity	N	Reference test for sensitivity
Influenza A virus	>100%	100%	198	Lateral flow test
Influenza B virus	100%	100%	122	Lateral flow test
Respiratory syncytial virus	100%	99.9%	198	Lateral flow test
SARS coronavirus 2	71%	100%	134	mariPOC® Respi+ or mariPOC® SARS-CoV-2
Group A streptococci	100%	~100%	193	Culture

**Table 14.** Cross-reaction and recognition spectrum data. The analysed microbial strains and pathogenpreparations are listed on the left and the analytespecific tests against which the sample has been analysed are listed on the right. A positive result is indicated by + (identifies/cross-reacts); an egative result is indicated by + (identifies/cross-reacts); and NAsignifies a combination that has not been studied.

	Influen	Influen	Respir	Human	Human	SARS	Human	Parainf	Parainf	Parainf	Strepto	Adeno	Group
	za A	za B	atory	metap	bocavir	corona	corona	luenza	luenza	luenza	сосси	virus	Α
	virus	virus	syncyti	neumo	us	virus 2	virus	1 virus	2 virus	3 virus	S		strepto
			al virus	virus			OC43				pneum		cocci
											oniae		
Analysed													
sample													

Influenza A virus (purified virus preparation): H1N1: A/New Caledonia/20/99 H3N2: A/Panama/2007/99 H3N2: A/Victoria/361/11 H3N2: A/Texas/50/12	+	-	_	-	-	-	-	-	-	-	-	-	-
Influenza A virus (purified virus preparation): H3N2: seasonal 2011-2012, Finland H3N2: A/New York/55/04	NA	-	-	NA	NA	NA	NA	-	-	-	-	-	NA
Influenza A virus (purified virus preparation): H7N3: A/Mallard/Netherlands/12/00	+	-	-	-	-	NA	-	-	-	-	-	-	NA
Influenza A virus (crude allantoic fluid): H7N9: A/Shanghai/2/2013	+	-	-	-	NA	NA	NA	-	-	-	-	-	NA
Influenza A virus (purified virus preparation): H1N1: A/California/07/09pdm H2N2: A/Singapore/1/57 H3N2: A/Hongkong/1/68/164 H9N2: A/Hongkong/1093/99	+	NA											
Influenza A virus (so-called avian flu, supernatant of virus culture): H5N1: A/rg/duck/HUMAN/795/02	+	-	-	-	-	NA	-	-	-	-	-	-	NA
Influenza A virus (so-called avian flu, supernatant of virus culture): H5N1: A/Vietnam/1194/2004 "NIBRG-14"	+	NA											
Influenza A virus (so-called swine flu, supernatant of virus culture): H1N1v: A/FIN/554/09	+	-	-	-	-	-	-	-	-	-	-	-	-
Influenza B virus (purified virus preparation): B/Hong Kong 5/72 B/Victoria/504/00	-	+	-	-	-	NA	-	-	-	-	-	-	-

	Influen	Influen	Respir	Human	Human	SARS	Human	Parainf	Parainf	Parainf	Strepto	Adeno	Group
	za A	za B	atory	metap	bocavir	corona	corona	luenza	luenza	luenza	coccu	virus	Α
	virus	virus	syncyti	neumo	us	virus 2	virus	1 virus	2 virus	3 virus	S		strepto
			al virus	virus			OC43				pneum		cocci
											oniae		
Analysed													
sample													

Influenza B virus (purified virus preparation): B/Qingdao/102/91	NA	+	-	NA	NA	NA	NA	-	-	-	-	-	NA
Influenza B virus (purified virus preparation): B/Florida/04/06	NA	+	-	-	NA	NA	NA	-	-	-	-	-	NA
Influenza B virus (purified virus preparation): Phuket/3073/2013	-	+	-	-	-	-	-	-	-	-	-	-	NA
Respiratory syncytial virus (purified virus preparation): Type A / Long	-	-	+	-	-	-	-	-	-	-	-	-	-
Respiratory syncytial virus (purified virus preparation): Type B / clinical strain (Labquality round 1, 2017)	-	-	+	-	-	-	-	-	-	-	-	-	-
Human metapneumovirus A and B (supernatant of virus culture)	NA	-	-	+	NA	NA	NA	-	-	-	-	-	NA
Human metapneumovirus (supernatant of virus culture)	-	-	-	+	-	-	-	-	-	-	-	-	-
Human bocavirus (recombinant VP2 antigen)	-	-	-	-	+	-	-	-	-	-	-	-	-
Human bocavirus (clinical specimen)	-	-	-	-	+	-	-	-	-	-	-	-	-
SARS coronavirus 2 (clinical specimen)	-	-	-	-	NA	+	-	-	-	-	-	-	NA
SARS coronavirus 2 (recombinant nucleoprotein)	-	-	-	-	-	+	-	-	-	-	-	-	NA
SARS coronavirus 1 (recombinant nucleoprotein)	-	-	-	-	-	+	-	-	-	-	-	-	NA
Human coronavirus OC43 (purified virus preparation or clinical sample)	-	-	-	-	-	-	+	-	-	-	-	-	-
MERS coronavirus (recombinant nucleoprotein)	-	-	-	-	-	-	-	-	-	-	-	-	NA
Human coronavirus strains 229E and NL63 (purified virus preparation), HKU1 (recombinant nucleoprotein)	NA	NA	NA	NA	NA	-	-	NA	NA	NA	NA	NA	NA
Parainfluenza 1 virus (purified virus preparation): Sendai	-	-	-	-	-	-	-	+	-	-	-	-	-
Parainfluenza 2 virus (purified virus preparation)	-	-	-	-	-	-	-	-	+	-	-	-	-

	Influen za A virus	Influen za B virus	Respir atory syncyti al virus	Human metap neumo virus	Human bocavir us		Human corona virus OC43	Parainf luenza 1 virus	Parainf luenza 2 virus	Parainf luenza 3 virus	Strepto coccu s pneum oniae	Adeno virus	Group A strepto cocci
Analysed sample													
Parainfluenza 3 virus (purified virus preparation): Washington/1957	-	-	-	-	-	-	-	-	-	+	-	-	-
C243 Streptococcus	_	-	-	-	-	NA	_	_	-	-	+	-	-
pneumoniae (purified antigen preparation)													
Streptococcus pneumoniae strain 4 (bacterial culture suspension inactivated by heating)	-	-	-	-	-	-	-	-	-	-	+	-	-
Streptococcus pneumoniae strains 1, 3, 6B, 7F, 9V, 14, 15, 18C, 19A, 19F, 23F (bacterial culture suspension inactivated by heating)	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	+	NA	NA
Adenovirus antigen preparation (hexon protein)	-	-	-	-	-	NA	-	-	-	-	-	+	-
Adenovirus strains 1-8, 14, 19, 21 (inactivated cell culture suspension or clinical sample)	NA	-	-	NA	NA	NA	NA	-	-	-	-	+	NA
Adenovirus strain 6 (inactivated cell culture suspension)	-	-	-	-	-	-	-	-	-	-	-	+	-
Adenovirus strain 40 (inactivated cell culture suspension)	NA	-	-	NA	-	NA	NA	-	-	-	-	+	NA
Group A streptococci / S.  pyogenes (inactivated and enriched bacterial preparation)	-	-	-	-	-	NA	-	-	-	-	-	-	+
Group A streptococci / S.  pyogenes (bacterial culture suspension inactivated by heating): ATCC 19615	-	-	-	-	-	-	-	-	-	-	-	-	+
Group C streptococci (bacterial culture suspension)	-	-	-	-	-	NA	-	-	-	-	-	-	-
Group G streptococci (bacterial culture suspension)	-	-	-	-	-	NA	-	-	-	-	-	-	-
Staph. aureus (bacterial culture suspension inactivated by heating): ATCC 29213	-	-	-	-	-	-	-	-	-	-	-	-	-

Staph.	-	-	-	-	-	-	-	-	-	-	-	-	-
epidermidis (bacterial													
culture suspension inactivated by													
heating)													
S. mitis (bacterial culture	-	-	-	-	-	NA	-	-	-	-	-	-	-
suspension inactivated by													
heating)													
S. mutans (bacterial culture	-	-	-	-	-	NA	-	-	-	-	-	-	-
suspension inactivated by													
heating): ATCC 25175													

Analysed	Influen za A virus	Influen za B virus	Respir atory syncyti al virus	Human metap neumo virus	Human bocavir us	SARS corona virus 2	Human corona virus OC43	Parainf luenza 1 virus	Parainf luenza 2 virus	Parainf luenza 3 virus	Strepto coccu s pneum oniae	Adeno virus	Group A strepto cocci
sample													
S.  agalactiae (bacterial culture suspension inactivated by heating): ATCC 13813	-	-	-	-	-	NA	-	-	-	-	-	-	-
S. bovis (bacterial culture suspension inactivated by heating): ATCC 9809	-	-	-	-	-	NA	-	-	-	-	-	-	-
S. sanguinis (bacterial culture suspension inactivated by heating)	-	-	-	-	-	NA	-	-	-	-	-	-	-
S. anginosus species: S. anginosus (1019, 3113, 3387, 4015, 5011, 7561, 7765, 8073), S. constellatus (3792, 5691) and S. intermedius (5380, 5643, 6194, 6418, 7404) (bacterial culture suspension inactivated by heating)	NA	-	-	-	NA	NA	NA	-	-	-	-	-	-
S. anginosus species: S. anginosus (209), S. constellatus (5690) and S. intermedius (1343) (bacterial culture suspension inactivated by heating)	-	-	-	-	-	-	-	-	-	-	-	-	-
H. influenzae (bacterial culture suspension inactivated by heating): ATCC 33391	-	-	-	-	-	-	-	-	-	-	-	-	-

H.	-	-	-	-	-	-	-	-	-	-	-	-	-	
parainfluenzae (bacterial culture														
suspension inactivated by														
heating): ATCC 33392														

According to the literature, about 5% of isolates of the *Streptococcus anginosus* species express

LancefieldgroupAsurfaceantigen, which is measured in the antigen detection test for *Streptococcus pyogenes*. Consequently, a sample containing *S. anginosus* bacterium may occasionally give false positive results in a test for group A streptococci. The frequency of *S. anginosus* carriage in respiratory epithelia is not reported in the literature. This, however rarely results in a false clinical diagnosis.

#### 6.2mariPOC® Gastro and CDITests

Table 15. Analytical sensitivities of the mariPOC® Gastro and CDI tests for standard samples.

Analyte	Analytical
	sensitivity
Norovirus GII.4	5 ng/ml recombinant antigen
Norovirus GI	6 ng/ml recombinant antigen
Rotavirus	0.5 ng/ml recombinant antigen
Adenovirus	7 ng/ml purified antigen
Campylobacter spp.	0.3 ng/ml purified antigen
C. difficile	0.7 ng/ml recombinant antigen
GDH	
	0.1 ng/ml purified toxin A when C. difficile GDH test is positive
C. difficile	1.5 ng/ml purified toxin A when <i>C. difficile</i> GDH test is negative
Toxin A	
	0.1 ng/ml purified toxoid B when <i>C. difficile</i> GDH test is positive
C. difficile	1.2 ng/ml purified toxoid B when <i>C. difficile</i> GDH test is negative
Toxin B	

Note! The analytical sensitivity of C. difficile Toxin A/B test is depended on the result in C. difficile GDH test.

**Table 16.** Clinical performance of the mariPOC® Gastro and CDI tests with stool samples compared to other laboratory methods. PCR was used to resolve discrepant results.

Analyte	Sensitivity	Specificity	N	Reference
				test for sensitivity
Norovirus GII.4	100%	99.5%	428	Lateral flow test
Norovirus GI	NA	99.5%	428	Lateral flow test
Rotavirus	100%	99.8%	651	Lateral flow test
Adenovirus	100%	99.5%	651	Lateral flow test
	>100% to LF			Lateral flow (LF) test and
Campylobacter spp.	91% to culture	97.5%	352	culture
C. difficile	100%	98.8%	188	Membrane enzyme immunoassay
GDH				
C. difficile	>100%	100%	188	Membrane enzyme immunoassay
Toxin A/B				

**Table 17.** Cross-reaction and recognition spectrum data. The analysed microbial strains and pathogenpreparations are listed on the left and the analytespecific tests against which the sample has been analysed are listed on the right. A positive result is indicated by + (identifies/cross-reacts); an egative result is indicated by + (identifies/cross-reacts); and NA signifies a combination that has not been studied.

	Norovirus GII.4	Norovirus GI	Rotavirus	Adenovir us	Campylo bacter spp.	C. difficile GDH	C. difficile Toxin A/B
Analysed sample							
Norovirus GII.4 (stool sample)	+	_	_	-	-	-	-
Norovirus GI.1 (recombinant virus-like particle)	-	+	-	-	-	NA	NA
Norovirus GI.3 (stool sample)	-	+	NA	NA	-	NA	NA
Norovirus GI.4 (stool sample)	NA	+	NA	NA	NA	NA	NA
Norovirus GI.6 (stool sample)	-	+	-	-	-	NA	NA
Rotavirus A, serotype G1, G2, G4 and G9 (stool samples)	-	-	+	-	-	NA	NA
Rotavirus A, serotype G3 (stool samples)	-	-	+	-	-	-	-
Adenovirus (stool sample)	-	-	-	+	-	-	-
Campylobacter coli (cultured bacterial suspension)	-	-	-	-	+	-	-
Campylobacter hyoilei (cultured bacterial suspension)	-	-	-	-	+	-	-
Campylobacter jejuni (cultured bacterial suspension)	-	-	-	-	+	-	-
Campylobacter  upsaliensis (cultured bacterial suspension)	-	-	-	-	+	NA	NA
Clostridium difficile (cultured bacterial suspension) Toxin production: Negative or only binary toxin Ribotype: 010, 033	-	-	-	-	-	+	-
Clostridium difficile (cultured bacterial suspension) Toxin production: Toxin A and/or B Ribotype: 016, 017, 019, 023, 027, 053, 056,	NA	NA	NA	NA	NA	+	+
078, 107, 126, 176, 251 Clostridium	NA	NA	NA	NA	NA	-	+
sordellii (cultured bacterial suspension)							
Astrovirus type 1 (inactivated cell lysate)	-	-	-	-	-	NA	NA
Aeromonas hydrophila (cultured bacterial suspension)	-	-	-	-	-	-	-
Bacillus cereus (cultured bacterial suspension)	-	-	-	-	-	-	-

Bacillus	-	-	-	-	-	NA	NA	
subtilis (cultured								
bacterial suspension)								

	Norovirus GII.4	Norovirus GI	Rotavirus	Adenovir us	Campylo bacter spp.	C. difficile GDH	C. difficile Toxin A/B
Analysed							
sample							
Campylobacter fetus ss. fetus (cultured bacterial suspension)	-	-	-	-	-	-	-
Campylobacter lari (cultured bacterial suspension)	-	-	-	-	-	-	-
Clostridium bifermentans (cultured bacterial suspension)	NA	NA	NA	NA	NA	-	-
Clostridium clostridioforme (cultured bacterial suspension)	-	-	-	-	-	-	-
Clostridium innocuum (cultured bacterial suspension)	NA	NA	NA	NA	NA	-	-
Clostridium novyi type A (cultured bacterial suspension)	NA	NA	NA	NA	NA	-	-
Clostridium perfringens (cultured bacterial suspension)	-	-	-	-	-	-	-
Clostridium orbiscindens / Flavonifractor plautii (cultured bacterial suspension)	-	-	-	-	-	-	-
Clostridium septicum (cultured bacterial suspension)	NA	NA	NA	NA	NA	-	-
Clostridium sporogenes (cultured bacterial suspension)	NA	NA	NA	NA	NA	-	-
Escherichia coli (cultured bacterial suspension)	-	-	-	-	-	-	-
Helicobacter pylori (cultured bacterial suspension, stool sample)	-	-	-	-	-	-	-

enteritidis (cultured bacterial suspension)  Salmonella group B (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella typhin (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Staphylococcus agalactiae (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)	Salmonella	_	_	_	_	_	_	_
bacterial suspension)  Salmonella group B (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Salmonella typhinurium (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus apalactia (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)								
Salmonella group B (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella group C (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus  Streptococcus  agalactiae (cultured bacterial suspension)  Streptococcus  spandina (cultured bacterial suspension)								
suspension) Salmonella group C (cultured bacterial suspension) Salmonella group C (cultured bacterial suspension) Salmonella (cultured bacterial suspension) Salmonella (cultured bacterial suspension) Salmonella (cultured bacterial suspension) Salmonella (cultured bacterial suspension) Shigella (cultured bacterial suspension) Staphylococcus aureus (cultured bacterial suspension) Staphylococcus epidermidis (cultured bacterial suspension) Streptococcus agaglactiae (cultured bacterial suspension) Streptococcus anginosus (cultured bacterial suspension) Streptococcus Streptococcus anginosus (cultured bacterial suspension)								
Salmonella group C (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)	Salmonella group B (cultured bacterial	-	-	-	-	-	-	-
suspension)  Salmonella typhi (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Salmonella typhimurium (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)	suspension)							
Salmonella typhi (cultured bacterial suspension)  Salmonella typhi (cultured bacterial suspension)  Salmonella typhimurium (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)	Salmonella group C (cultured bacterial	-	-	-	-	-	-	-
typhi (cultured bacterial suspension)  Salmonella typhimurium (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)	suspension)							
bacterial suspension)  Salmonella typhimurium (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial suspension)	Salmonella	-	-	-	-	-	-	-
Salmonella typhimurium (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus analyse (cultured bacterial suspension)	typhi (cultured							
typhimurium (cultured bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	bacterial suspension)							
bacterial suspension)  Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)	Salmonella	-	-	-	-	-	-	-
Shigella dysenteriae (cultured bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus	typhimurium (cultured							
dysenteriae (cultured bacterial suspension)       -	bacterial suspension)							
bacterial suspension)  Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	Shigella	-	-	-	-	-	-	-
Staphylococcus aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	dysenteriae (cultured							
aureus (cultured bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus o o o o o o o o o o o o o o o o o o o	bacterial suspension)							
bacterial suspension)  Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus boxis (cultured bacterial suspension)  Streptococcus	Staphylococcus	-	-	-	-	-	-	-
Staphylococcus epidermidis (cultured bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	aureus (cultured							
epidermidis (cultured bacterial suspension)  Streptococcus	bacterial suspension)							
bacterial suspension)  Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	Staphylococcus	-	-	-	-	-	-	-
Streptococcus agalactiae (cultured bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	epidermidis (cultured							
agalactiae (cultured bacterial suspension)  Streptococcus	bacterial suspension)							
bacterial suspension)  Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	Streptococcus	-	-	-	-	-	-	-
Streptococcus anginosus (cultured bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	agalactiae (cultured							
anginosus (cultured bacterial suspension)  Streptococcus	bacterial suspension)							
bacterial suspension)  Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	Streptococcus	-	-	-	-	-	-	-
Streptococcus bovis (cultured bacterial suspension)  Streptococcus constellatus (cultured bacterial	anginosus (cultured							
bovis (cultured bacterial suspension)  Streptococcus	bacterial suspension)							
bacterial suspension)  Streptococcus  constellatus (cultured bacterial	Streptococcus	-	-	-	-	-	-	-
Streptococcus	bovis (cultured							
constellatus (cultured bacterial	bacterial suspension)							
	Streptococcus	-	-	-	-	-	-	-
suspension)	constellatus (cultured bacterial							
	suspension)							

Analysed sample	Norovirus GII.4	Norovirus GI	Rotavirus	Adenovir us	Campylo bacter spp.	C. difficile GDH	C. difficile Toxin A/B
Streptococcus intermedius (cultured bacterial suspension)	-	-	-	-	-	-	-
Streptococcus mitis (cultured bacterial suspension)	-	-	-	-	-	-	-

Streptococcus	-	-	-	-	-	-	-
mutans (cultured							
bacterial suspension)							
Streptococcus	-	-	-	-	-	-	-
pyogenes (cultured							
bacterial suspension)							
Streptococcus	-	-	-	-	-	-	-
sanguinis (cultured							
bacterial suspension)							
Yersinia	-	-	-	-	-	-	-
enterocolitica avirul. (cultured bacterial							
suspension)							
Yersinia	-	-	-	-	-	-	-
enterocolitica 0:3 (cultured bacterial							
suspension)							

Clostridium sordellii produces haemorrhagic toxin (HT) and lethal toxin (LT) which have a high homologywith Clostridium difficile toxin AandtoxinB, respectively. C. sordellii is abacterium which may cause infections with a very high mortality rate. C. sordellii infections (caused by HT and LT) are rare but may occur after an injury, surgical procedure, drugin jection, child birthormedically induced abortions. Symptoms of C. sordellii infection are pain, nausea, vomiting and diarrhoea. Cross-reaction with C. sordellii toxins is a known property of the mari POC® toxin A/B test and some other commercially available C. difficile toxin tests. However, mari POC® GDH test does not detect C. sordellii. Both the mari POC® GDH and the Toxin A/B tests must be positive to confirm the positivity for CDI. See chapters 7.3.6 and 10.3 for more information about the results.

#### 7 Using the Test System

#### 7.1 Deployment of the Test System

The installation of the test system is carried out by the manufacturer's representative. The test system and the measuring program must be kept switched on to enable automatic rinsing.

## 7.2mariPOC® Software (ArcDiagnoser™ MeasuringProgram)

The main window of the mariPOC® Software (ArcDiagnoser™ measuring program i.e. the user interface) is explained in Figure 9. Letters in the image indicate the main features of the main window. The measuring program is divided into the patient information section and the report section. The function buttons (A, B and C) and a drop-down menu (D) are along the top of the measuring program's left pane. Below these the patient information lines, which may be selected one at a time, are displayed. The selected line is indicated by a blue highlight (E) whereas the unselected lines are light-coloured (F). If a patient information line is bold, its results have not yet been viewed. The results for the selected patient are shown in the report section (right pane). The test status which is shown in the patient information line is explained in Table 18.

**Figure 9.** Main window of the mariPOC® Software (ArcDiagnoser™ mariPOC®+ measuring program) with its features marked by letters (example from mariPOC® RTI combi test plate in use).

 $The news ample button \textbf{(A)} is pressed to open the "Patient information" window for entry of a new patient's information ( \underline{\textbf{Figure}} ) and the patient information of the patient$ 

10). Inorder to identify the patient, at least one of the following fields

must be filled: "First name", or "IDcode". The identification code field is free-form. The test type is selected from the "Test type" drop-down menu. The test types to be selected in the mariPOC RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the maripoc RTI combite style are according to the selected in the se

ThemariPOC®Softwareshowsonlythose teststhatcanbeselectedfromthetestplateinuse. The "Rapidinstruction" drop-downmenuallows the selection of the rapid instruction displayed on-screen. This selection, however, is only instructional and does not affect the analysis. If not selected, the default setting is without rapid instruction display. Additional information such as symptoms may be entered in the "Other information" field. Theinformation is shownonly in the printed results report and when the patient information line is double clicked to open "Patient information" window.

The "Read code" button is active only when the test system has been connected to a laboratory information system (LIS). In a test system connected to a LIS, patient information and the type of test ordered will be automatically filled once the sample referral bar code has been read with a separate reader.


Figure 10. "Patient information" window that opens when the new sample button is clicked (example from mariPOC® RTI combi test plate in use). The shown test types are depended on the test plate in use. "External quality assessment sample" selection is available only if the mariPOC® testsystemisconnectedtomariCloud™ onlineservice. Whenavailable, these lections hould be used when an external quality assessment (EQA) sample is analysed. "Read code" is used when the mariPOC® test system is connected to Laboratory or Hospital Information System(HIS/LIS).

Newlyenteredpatientinformation can be deleted by clicking the "Cancel" button. When the patient information has been entered, an individual bar code label is printed by clicking the "Print" button. A new patient information line is then created in the bottom of the patient information section of the mariPOC® Software. When the new patient information line has been selected a rapid instruction appears on the right side of the measuring program.

Information on control samples does not need to be entered separately because their factory installed bar code labels are read automatically once inserted into the analyser. The information is automatically transferred to the measuring program.

"External quality assessment sample" selection is available only if the mariPOC® test system is connected to mariCloud™ online service (**Figure 10**). When available, the selection should be used

whenanexternal quality assessment (EQA) sample is an alysed. If not selected, the default setting is a "Patient sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" does not affect the sample analysis or result reporting to mariPOC ® Software.



When the Test type has been selected (**Figure 10**) the pathogens detected with the selected test type are visualised on the right side (the report section) of the mariPOC® Software until the results are reported (**Figure 11**).

**Figure 11**. Main window of the mariPOC® Software (ArcDiagnoser™ measuring program) when the Testtypeisselectedin"Patientinformation"window(examplefrommariPOC®RTIcombitestplate in use).

Table 18. Terms and explanations illustrating analysis (test) status shown in the measuring program.

Test status	Explanation
Insert sample	The sample information has
	been entered and the bar code label printed. The sample treatment protocol
	is
	shown in the report section. The analyser is waiting for a sample tube.
Processing	The analyser is dispensing
	a new sample or is waiting for the result from the first time point.

Pending	Dispensing has not started yet because either several patient samples were inserted at the same time, and/or the test plate is full, and there is not enough space for all the samples on the same test plate.
Preliminary	The preliminary analysis (first measurement) result is ready. Only the positive results are reported.
Finished	The analysis is complete. Negative results are also reported if the analysis is allowed to continue until the final results.
"Preliminary" or	Analysis has failed. There
"Finished" text in red	has been a failure during one of the phases of the analysis, which hinders
	reporting of the results for one or more analytes.

There are three time bars on the bottom of the patient information section (<u>Figure 9</u>). The time remaining for inserting next sample(s) is indicated in the "Ready for new sample in" time bar (**G**).

Thistimebarchangesinto "Readyfornewtestplatein" when there is an opportunity to change the

testplate. The time remaining before the results are ready can be seen for each patient by selecting the patient line in question. Then the "Preliminary result in" time bar (H) on the bottom of the measuring program's main window indicates the remaining time for the completion of the preliminary results and, correspondingly, the "Final result in" time bar (I) indicates the remaining time for the final results. The top part of the report section (on the right) shows the number of remaining multianalyte tests on the current test plate (J).

Note! Quick Flu/RSV (or Quick Flu+) test consumes Respi (or Respi+) tests and Quick StrepA test consumes Pharyn tests when a mariPOC® RTI combi (or combi+) test plate is in use.

The analysis status and identity information of these lected patient's (marked with ablue line in the patient information section) is indicated by a yellow or green bar ( $\mathbf{K}$ ). Yellow indicates Preliminary results and green Final results. The analysis results are shown below. The analytes tested are listed in the column  $\mathbf{L}$ . If the analysis qualitative result in column  $\mathbf{M}$  is positive, it is shown first. After obtaining the final results, a red exclamation mark (!) can appear next to the negative result in the column  $\mathbf{M}$ . It indicates that a positive preliminary result has changed into a negative final result.

However, apositive preliminary resultrarely changes into an egative final result (approximately one sample per 400 samples). The column  $\psi$  (psi, indicated with  $\mathbf{N}$  in Figure 9) provides additional quantitative information about the pathogen levels in the sample (see chapter 7.3.6).  $\psi$  feature is optional. The last column ( $\mathbf{O}$ ) displays the result of the internal quality controls (autoverification) indicating the technical success of the analysis (OK/Failed). The analysis report for the selected patient( $\mathbf{E}$ ; indicated with blue background) can be printed on an external printer by clicking the print results button ( $\mathbf{B}$ ). The report for customer support ( $\mathbf{C}$ ), created in case of malfunction or for invoicing, includes an onymized results, the system log file, the full results of failed samples and control samples from the last 60 days, and the amount of tests performed.

In the patient information section (left pane) under the "More options" drop-down menu (**D**) are the following options: Maintenance wizard, Control data, Reports, About mariPOC and Change test plate. The "Maintenance wizard" guides the maintenance operations by giving instructions on how to empty the waste container, to change the Wash and System solution container and to shut down theanalyser. The "Controldata" reportallowsmonitoring results from single analytes in the positive and negative control samples. The report will be shown automatically in the web browser. The purpose of the report is to demonstrate the performance of the analyser and the tests in order to track possible trends. A blue dot means that the measurement has been successful. A red dot indicates either an unsuccessful measurement or a result that is contrary to the expected value (+ or -). The quantitative results (Y-axis, signal) of the control samples are plotted in the order of analysis (X-axis, date or week). "Reports" opens a report creation pop-up window where Epidemiological report, Testsday by day and/ormari POC results (summary reports) can be created. The selected report will be shown automatically in the web browser. See chapter 7.3.6 for more information about the reports. "About mari POC" includes information about the manufacturer. "Change test plate" allows test plate change at any time (see chapter 7.5).

The test system is equipped with a self-diagnostic error-reporting system. Thus, the system automatically reports most of the

The test system is equipped with a self-diagnostic error-reporting system. Thus, the system automatically reports most of the possible errors to the screen. The report may contain a possible reason for failure and possible actions for restoring the function of the test system. It is recommended to always notify customer support about any errors.

## 7.3 Performing the Test and Reading the Results

The clinical suspicion (indication) determines the sampling location, the selected test type, and the pretreatment of the sample. The test plate in use determines the target pathogen coverage of the test (see <u>Table 4</u>, <u>Table 5</u> and <u>Table 6</u>).

7.3.1Sampling

For the Respi+, Respi, Respi < 7 years old, Quick Flu+, Quick Flu/RSV and SARS-CoV-2 tests, the sample is taken from the mucosa of the respiratory tract nasopharynx by rubbing with a swab or collecting a standardnasopharynge alaspirate. The swabsampling must be done using flocked swabs defined in the User's manual (see

 <u>Table 7</u>). It is beneficial to use as large a swab as possible, considering patient size, because the sample volume directly affects test performance. Nasopharyngeal wash samples are not recommended because they are dilute. The manufacturer disclaims any responsibility if any other sample materials are used in the mariPOC® testsystem.

Forthe**Pharyn**and**QuickStrepAtests**, the sample is typically taken from the throat or the perianal area depending on the symptoms. The sampling must be done using flocked swabs defined in the User's manual (see <u>Table</u>

<u>7</u>). Arigidlargeswabisrecommended to be used for sampling because the sampling volume has a direct effect on test performance. For the **Gastro** and **CDI tests**, the sample material is stool (faeces) from patients with symptoms of acute gastroenteritis. Stool sample should be collected to a clean container.

#### 7.3.2Storage of Samples

Refrigerated storage of the samples for several days, or freeze-thaw cycles, are known to have a deleteriouseffectonthesensitivityofallantigendetectiontests. Itisrecommended, therefore, that the sample is analysed as soon as possible following sampling. See **Table 19** for manufacturer's recommendations for storage temperatures and times. Before analysis, nasopharyngeal and throat swabsamplescanbestoredinRTIsamplebuffer. However, swabsamplesare preferred to be stored without the sample buffer. The mariPOC® Sample tube must be frozen in upright position with parafilmsealing the captoprevent any leakage. Thaw the frozen sample totally before pretreatment.

Table 19. Storage temperatures and times of samples.

Phase	Storage	
Transport	Refrigerated	
	+2 to +8°C up to 2 days/	
Before analysis	-20 to -80°C over 2 days	
	+2 to +8°C up to 2 days/	
Leftover samples	-20 to -80°C over 2 days	

Note! Samples should not be stored in any kind of transport or storage media or buffers. The preferred way of storing the samples is in their naïve form. Transport and storage media and buffers can affect adversely to the stability of the sample and the performance of the test.

## 7.3.3 Respi+, Respi, Respi < 7 Years Old, Quick Flu+, Quick Flu/RSV and SARS-CoV-2 Tests

The pretreatment of the swab, aspirate and wash samples differs and in this manual they are referred to as A (swab), B (aspirate), C (wash, concentration protocol) and D (wash). Each sample type's pretreatment procedures are described separately in this chapter in between printing the sample bar code and inserting the pretreated sample into the analyser.

## Printing Bar Code

Click the new sample button in the top left corner of the mariPOC® Software. The "Patient information" pop-up window (Figure 12) opens. Enter patient information into at least one of the following fields: First name, Last name, and ID code (identifier). Depending on the test plate in use, selectthetesttypeRespi+,Respi,Respi<7yearsold,QuickFlu+,QuickFlu/RSVorSARS-CoV-2from the "Testtype" drop-downmenu. Thepathogensdetected with the selected testtype are visualised to the rightside (the report section) of the mariPOC® Software until the results are reported (Figure 11).

Respi+ and Respi tests detect 11 pathogens and reports the preliminary results in 20 minutes and final results in 2 hours. Respi+ test includes a test method for SARS-CoV-2. Because of the high frequency of Pneumococcus carriage in children under 7 years, the manufacturer recommends selecting the Respi < 7 years old test for young children. This is a Respi+ or Respi test without Pneumococcus.

Quick Flu+ and Quick Flu/RSV rapid tests reports influenza A virus, influenza B virus and respiratory syncytial virus (RSV) in 20 minutes. Quick Flu+ test also includes a test method for SARS-CoV-2. The Quick Flu+ and Quick Flu/RSV tests can be selected from the Combi+ or Combi test plates, respectively, only if the Quick feature is enabled.

The SARS-CoV-2 test method in Respi+, Quick Flu+ and SARS-CoV-2 tests detects SARS-CoV-1 and SARS-CoV-2.SARS-CoV-2 testcanbeselected only if the mariPOC® SARS-CoV-2 test plate (REF1204S) is in use. The SARS-CoV-2 test reports the preliminary results in 20 minutes and final results in 95 minutes.

Theusermayselecttherapidinstructionappearingon-screeninthe "Rapidinstruction" drop-down menu (informative selection, no effect on analysis) and enterany notes or symptoms in these parate "Other information" field. Both fields are for information only and do not affect the test.

service. When available, the selection should be used whe externalqualityassessment(EQA)sampleisanalysed.Ifnot sample"andtheresultmaydistortthereal-timeepidemiologic does not affect the sample analysis or result reporting to	selected,thedefaultsettingisa"Patient calsurveillancedata.Theselectionof "External quality assura	ance sample"
<b>Figure 13.</b> Photograph showing how bar code labels mathematic Anewlineforanewpatient's information has been created. The status's section. The test status is now in the "Inserts ample" pland the patient information cannot be changed after the patient in the patient information cannot be changed after the patient in the	elabelisparallelwiththelengthof the sample tube (Figure 13) ay be attached to a sample tube. The progress of the test for each patient can be followed in the "Te hase. The bar code label is printed. If there is a problem in attaching elabel is wrinkled or defaced in some way, an ewbar code label in the label is wrinkled or defaced in some way, an ewbar code label in the label is wrinkled or defaced in some way, an ewbar code label in the label is wrinkled or defaced in some way, an ewbar code label in the label in the label is wrinkled or defaced in some way, an ewbar code label in the label in t	est g
nostril (according to the patient age and size) and rub the mucosa adhere to the swab. It is recommended that the pinformation about the nasopharyngeal swab sampling is <b>Figure 14.</b> Swab sampling.  Note! Always use the swabs defined in the User's manual Note!Iftwoswabsamplescollectedfromthepatient, one from		cells from the collected. More
	onfibreheadoftheshaftintothe mariPOC® Sample tube as s	

15. Ensure that the patient information on the bar code label of the sample tube is for the correct patient.

Figure 15. Cutting off a swab into a sample tube.

Safety!Cleanthescissorscarefullybetweeneachsamplingusing70%ethanolorsimilar.Wipethemwithdisposable paper.

Place diagonally the bottom of the sample tube to the bottletop dispenser's stand below of the dispensing head and push the tube between clips. Add 1.3 ml of RTIs ample buffer to the sampletubebyliftingthebottletopdispensertopupanddownonce(Figure 16). Afterdispensing, draw the tube horizontally away from the stand's clips. Seal the sample tube with acap.

m protocols.io 34 08/28/2020

#### Figure 16. Dispensing with the bottletop dispenser.

Note! The bottletop dispenser's standisprovided to minimize the contamination of the dispensing head and forease of use. The sample tube should not be lifted upwards when using the stand.

Note! If the bottletop dispenser has not been used for a long time or its protective cap has been left open, dispense into a waste container a few times to expel the air from the dispensing head.

Safety! The RTI sample buffer can be dispensed to the sample tube (<u>Figure 16</u>) before sampling (<u>Figure 14</u>) and cutting the swab into the tube (<u>Figure 15</u>). This eliminates aerosol formation and release during sample pretreatment.

Safety!Avoidtouchingthedispensingheadwiththesampletubeorspillinganysolutiononbareskin,eyes,ormucous membranes (see the cleaning instructions for the dispensing head in chapter 10.3). If any solution spills on the skin oreyes,wash withplentyofwaterandconsultadoctorifnecessary. TaketheUser'smanualandSDSswithyou.

Mix the sample tube with a vortex mixer for about 10-15 seconds (Figure 17).

### Figure 17. Mixing the sample tube.

Note! Press firmly on the top of the sample tube cap during mixing (Figure 17) so that a vortex forms inside the sampletube. The purpose of mixing istorelease the sample from the swabor mucus into the sample solution. Mixing that does not last long enough or is not strong enough (i.e., no vortex forms) leads to an incomplete release of the sample from the swab or mucus and thus less sensitive testresults.

B. Aspirate Sample Collection and Pretreatment

The tubing of the aspirate collection system (for example syring ewith tubing) is inserted through the nose into the nasophary nx and mucus is aspirated from both nostrils.

 $\label{linear_problem} \mbox{Dispense approximately 0.3 ml of the native nasopharyngeal aspirate (i.e., untreated) into the mariPOC \mbox{$\mathbb{B}$ Sample tube.} }$ 

Place diagonally the bottom of the sample tube to the bottletop dispenser's stand below of the dispensinghead and push the tube between clips. Add 1.3 mlof RTIs ample buffer to the sample tube by lifting the bottletop dispenser to pupand down once (Figure 16). After dispensing, draw the tube horizontally away from the stand's clips. Seal the sample tube with a cap.

Mixthesampletubewithavortexmixerforabout30seconds(Figure 17). Letthesamplesettle for 2-10minutes.

Mixthesampletubewithavortexmixeragainforabout 10 seconds. Centrifugethesampletube at 1000 g for 5 minutes. Do not allow the pellet to be mixed or swayed again in order to avoid the dispenser needle aspirating the pelleted mucus. Safety! The mariPOC® Sample tube does not withstand higher g-forces than 1000 g.

C. Wash Sample Collection and Pretreatment with ConcentrationProtocol

Nasopharyngeal wash sample is not preferred sample material. It should only be used for patients who can be sampled within 5 days from the onset of respiratory infection symptoms. For wash

samplepretreatmentusetheconcentrationprotocol(C)ifpossible. The performance specifications stated by the manufacturer in terms of analytical and clinical sensitivity are valid for samples obtained using flocked swabs or by aspiration without saline. If the observed performance with nasopharyngeal wash samples does not match with the specifications of the manufacturer or the results reported in the literature, please use nasopharyngeal swabs and/or aspirates (no saline addition), which are primarily

recommended by themanufacturer.

The tubing of the wash collection system (for example syringe with tubing) is inserted through the nose into the nasopharynx. Use preferably about 1-2 ml of saline to collect the sample. No

viraltransportmediaisallowed. Aspiratemucus from bothnostrils and dispense the sample into a high force centrifugation tube.

Centrifuge entire washs ample (minimum of 0.6 ml) for 5 min 14000 ginhigh for cecentrifugation tube. Discard supernatant so that approximately 0.3-0.4 ml of the sample is left.

Safety! The mariPOC® Sample tube does not withstand higher g-forces than 1000 g.

Add1.3mlofRTIsamplebufferdiagonallytothesampletubebyliftingthebottletopdispenser top up and down once (**Figure 16**). Be careful not to contaminate the dispensinghead.

Mix the sample tube with a vortex mixer for about 30 seconds (**Figure 17**). Transfer the sample toamariPOC®Sampletube. Sealthesampletube with a cap. Letthesample settle for 2–10 min.

Mixthesampletubewithavortexmixeragainforabout10seconds. Centrifugethesampletube at 1000 g for 5 minutes. Do not allow the pellet to be mixed or swayed again in order to avoid the dispenser needle aspirating the pelletedmucus.

D. Wash Sample Collection and Pretreatment

Nasopharyngeal wash sample is not preferred sample material. It should only be used for patients who can be sampled within 5 days from the onset of respiratory infection symptoms. For wash

samplepretreatmentusetheconcentrationprotocol(C)ifpossible. The performance specifications stated by the manufacturer in terms of analytical and clinical sensitivity are valid for samples obtained using flocked swabs or by aspiration without saline. If the observed performance with nasopharyngeal wash samples does not match with the specifications of the manufacturer or the results reported in the literature, please use nasopharyngeal swabs and/or aspirates (no saline addition), which are primarily recommended by themanufacturer.

The tubing of the wash collection system (for example syringe with tubing) is inserted through the nose into the nasopharynx. Use preferably about 1-2 ml of saline to collect the sample. No

vir altransport media is allowed. As pir a temucus from both no strils and dispense the sample into a tube.

Dispense approximately 0.6 ml of the nasopharyngeal wash sample into the mariPOC® Sample tube.

Place diagonally the bottom of the sample tube to the bottletop dispenser's stand below of the dispensinghead and push the tube between clips. Add 1.3 mlof RTIs ample buffer to the sample tube by lifting the bottletop dispenser to pupand down once (Figure 16). After dispensing, draw the tube horizontally away from the stand's clips. Seal the sample tube with a cap.

Mixthesampletubewithavortexmixerforabout30seconds(Figure 17). Letthesamplesettle for 2-10minutes.

Mixthesampletubewithavortexmixeragainforabout10seconds. Centrifugethesampletube at 1000 g for 5 minutes. Do not allow the pellet to be mixed or swayed again in order to avoid the dispenser needle aspirating the pelletedmucus. Safety! The mariPOC® Sample tube does not withstand higher g-forces than 1000 g.

Inserting Sample into Analyser

When the sample hatch's LED light is green, the analyser is ready for a new sample. Open the sample hatch, remove the old sample tubes, and insert a new sample tube into the rack. The patient information on the bar code label should face the user (Figure 18) so that the analyser is able to read the bar code from behind. The analyser automatically starts processing the sample after the sample hatch is closed. The hatch becomes locked for a few minutes per sample while dispensing. Already dispensed samples can be removed before the analysis results are ready. If required, samples can be stored according to instructions in chapter "7.3.2 Storage of Samples".

Figure 18. Proper position of the sample tube in the sample tube rack.

Note! In most cases the sample hatch locks immediately after the hatch is closed. If, however, the analyser is in the process of measuring a sample, there can be a delay of about 30 seconds before the hatch locks.

Note! The sample tube rack can hold 1–6 sample tubes at a time. Old samples that have been already processed do not need to be removed each time the sample hatch is opened. However, the measuring program notifies that position of the sample tube rack where there already is a dispensed sample. Position number 1 is on the left edge of the rack.

## 7.3.4 Pharyn and Quick StrepA Tests

The swab sample can be collected either from the throat or perianal area depending on the indication. The collection procedures for both sample types are described later in this chapter. Printing the bar code and the pretreatment are the same for both sample types.

#### Printing Bar Code

Click the new sample button in the top left corner of the mariPOC® Software. The "Patient information" pop-up window (Figure 19) opens. Enter patient information into at least one of the following fields; First name, Last name, and ID code (identifier). Select the Pharyn or Quick StrepA test. The pathogens detected with the selected test type are visualised on the right side (the report section) of the mariPOC® Software until the results are reported.

TheQuickStrepAtestidentifiesonlygroupAstreptococciandtheresultsarereportedin15minutes. Instead, Pharyn test reports preliminary results in 15 minutes and final results in 55minutes.

Theusermayselecttherapidinstructionappearingon-screeninthe "Rapidinstruction" drop-down menu and enter any notes or symptoms in the separate "Other information" field. Both fields are for information only and do not affect thetest.

"External quality assessment sample" selection is available only if the mariPOC® test system is connected to mariCloud™ online service. When available, the selection should be used when an

external quality assessment (EQA) sample is an alysed. If not selected, the default setting is a "Patient sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the result may distort the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the real-time epidemiological surveillance data. The selection of "External quality assurance sample" are the real-time epidemiological surveillance data. The selection of "External quality assurance sample" and the real-time epidemiological surveillance data. The real-time epidemiological surveillance data are the rea

**Figure 19.** "Patient information" pop-up window: before and after entering patient information (example from mariPOC® Pharyn test plate in use).

Printthebarcodelabelforthesampletubebyclickingthe "Print" button. Attachthebarcodelabel for the sample on the middle of the sample tube so that the text on the bar code label is parallel with the sample tube (**Figure 20**).

Figure 20. Photograph showing how bar code labels may be attached to a sample tube.

does not affect the sample analysis or result reporting to mariPOC® Software.

Anewlineforanewpatient'sinformationhasbeencreated. The progress of the test for each patient can be followed in the "Test status" section. The test status is now in the "Insert sample" phase.

Note! The patient information cannot be changed after the bar code label is printed. If there is a problem in attaching the printed barcode label to the sample tube, for example if the label is wrinkled or defaced in some way, a newbarcode label may be printed by double-clicking the patient information line and then clicking the "Print" button.

## A.Throat SwabCollection

The patient's tongue is pressed downwards with a spatula or held with fingers and gauze. Vigorously rubthetons ils and the posterior wall with a swabs other cells are collected on the swab ( $Figure\ 21$ ). Avoid contacting the mucous of the cheek or the tongue in order to collect as much sample from the throat as possible.

Note! Eating and drinking just before sampling may reduce the sensitivity of the analysis. Accordingly, it is recommended that the patient does not drink for at least one hour before the throat swab is collected. In addition, the use of antiseptic throat tablets and mouthwashes for relieving the symptoms of mouth and throat inflammations hould be avoided before sampling.

Note! Always use the swabs specified in the User's manual (Table 7).

Note! Always use larges wabs for a dults. If two swabs amples collected from the patient, one from the nasophary nx and one from the throat, are to be run in a single test, the samples must be collected using two swabs and only a single swab may be large throat swab. Inserting two large swabs into a single sample tube may lead to analyse rmal function.

#### **B.Perianal SwabCollection**

The perianal swab sample is collected with similar large and stiff flocked (dry) swab (**Table 7**) as the throat sample by rubbing carefully the surroundings of the anus. A swab sample containing visible traces of stool should be discarded and a new sample taken after cleaning the sampling area.

Pretreatment		
22. Figure 22. Cutting off a swab into a sample tube.	lonfibreheadoftheshaftintothe mariPOC® Sample tube as ing 70% ethanol or similar. Wipe them with disposable pap	
<b>Figure 23.</b> Adding the Extraction solutions.  Note! Do not combine the Extraction solutions A and B be	usmembranes.Ifanysolutionspillsontheskinoreyes, wash	

## Figure 24. Mixing the sample tube.

extraction to takeplace.

Note! Press firmly on the top of the sample tube cap during mixing (Figure 24) so that a vortex forms inside the sampletube. The purpose of mixing is to release the sample from the swab into the Extraction solution. Mixing that does not last longenough or is not strong enough (i.e., novortex forms) leads to an incomplete release of the sample from the swab and incomplete extraction and thus less sensitive test results.

Mix the sample tube with the vortex mixer for about 10-15 seconds (Figure 24). Let the tube stand for 2-10 minutes for the

Note! The maximum standing time under the influence of the Extraction solution is 30 minutes. Adding the RTI sample buffer terminates the extraction reaction.

Removethecapandplacediagonallythebottomofthesampletubetothebottletopdispenser's stand below to be the sample could be stand below to the tube between clips. Add 1.3 ml of RTI sample buffer to the sample tube by lifting the bottletoponce (Figure 25). After dispensing, draw the tube horizontally away from the stand's clips. Seal the sample 25. Dispensing with the bottletop dispenser.  Note! The bottletop dispenser's standisprovided to minimize the contamination of the dispensing head and for the sample tube to the sample tube by lifting the bottletop dispenser.	
bush the tube between clips. Add 1.3 ml of RTI sample buffer to the sample tube by lifting the bottletop since (Figure 25). After dispensing, draw the tube horizontally away from the stand's clips. Seal the sa Figure 25. Dispensing with the bottletop dispenser. Note! The bottletop dispenser's standisprovided to minimize the contamination of the dispensing head and for	
ush the tube between clips. Add 1.3 ml of RTI sample buffer to the sample tube by lifting the bottletop nce (Figure 25). After dispensing, draw the tube horizontally away from the stand's clips. Seal the saigure 25. Dispensing with the bottletop dispenser.  **Idote!Thebottletopdispenser's standisprovided to minimize the contamination of the dispensing head and formula to the sample tube.	
should not be lifted upwards when using thestand. Note! If the bottletop dispenser has not been used for a long time or its protective cap has been left ope container a few times to expel the air from the dispensing head.	ample tube with a cap.
Safety!Avoidtouchingthedispensingheadwiththesampletubeorspillinganysolutiononbareskin,eyes,orm cleaning instructions for the dispensing head in chapter <u>10.3</u> ). If any solution spills on the skin or eyes, and consult a doctor if necessary. Take the User's manual and SDSs withyou.	•
Mix the sample tube with the vortex mixer for about 10–15 seconds ( <b>Figure 24</b> ).  Note! Press firmly on the top of the sample tube cap during mixing so that a vortex forms inside the same	mple tube.
nserting Sample into Analyser	
and insert a new sample tube into the rack. The patient information on the bar code label should face to the analyser is able to read the bar code from behind. The analyser automatically starts processing the match is closed. The hatch becomes locked for few minutes per sample while dispensing. Already disperience the analysis results are ready. If required, samples can be stored according to instructions in characteristics.  Samples".  Figure 26. Proper orientation of the sample tubes in the sample tube rack.  Note! In most cases the sample hatch locks immediately after the hatch is closed. If, however, the analysmeasuring a sample, there can be a delay of about 30 seconds before the hatch locks.	e sample after the sample ensed samples can be removed apter "7.3.2 Storage of
Note! The sample tube rack can hold 1–6 sample tubes at a time. Old samples that have been already premoved each time the sample hatch is opened. However, the measuring program notifies that position where there already is a dispensed sample. Position number 1 is on the left edge of the rack.  7.3.5Gastro and CDI Tests Printing BarCode Click the new sample button in the top left corner of the mariPOC® Software. The "Patient information Figure 27). Enter patient information into at least one of the following fields; Firstname, Lastname, and/orIDcode (identifier). Selectthetesttype (describedin Figure 3).	n of the sample tube rack
ype" drop-down menu. The pathogens detected with the selectedtesttypearevisualisedontherightside(thereportsection)ofthemariPOC®Softwareuntil the result	ts are reported.
Gastro or GastroVir (without Campylobacter spp.) are available for mariPOC® Gastro test plate (2017M),Gastro+CDI,GastroVir+CDI,Gastro,GastroVirorCDIformariPOC®GastroCDIcombitest olate(2027M)andCDIformariPOC®CDItestplate(2037M).Thepreliminaryresultsarereportedin 20 minuto (2027M) and CDI the rapid instruction to appear on-screen from the "Rapid instruction" drop-down the separate "Other information" field. The last two fields are for information only and do not affect the	menu and enter any notes in
, and the state of	

"External quality assessment sample" selection is available only if the mariPOC® test system is connected to mariCloud™ online service. When available, the selection should be used when an externalqualityassessment(EQA)sampleisanalysed.Ifnotselected,thedefaultsettingisa"Patient sample"andtheresultmaydistortthereal-timeepidemiologicalsurveillancedata. Theselection of "External quality assurance sample" does not affect the sample analysis or result reporting to mariPOC® Software. Figure 27. "Patient information" pop-up window before and after entering patient information (example from mariPOC® Gastro CDI combi test plate inuse). Printthebarcodelabelforthesampletubebyclickingthe "Print" button. Attachthebarcodelabel tothemiddleofthesampletubesothatthetextonthebarcodelabelisparallelwiththelengthof the sample tube (Figure 28). Seal the sample tube with acap. Figure 28. Photograph showing how bar code labels may be attached to a sample tube. Anewlinefornewsample'sinformationhasbeencreated. The progress of the test for each sample canbefollowed in the "Test status" section. The test status is now in the "Insert sample" phase. Note! The patient information cannot be changed after the bar code label is printed. If there is a problem in attaching theprintedbarcodelabeltothesampletube, forexampleifthelabeliswrinkledordefacedinsomeway, anewbarcode label may be printed by double-clicking the patient information line and then clicking the "Print" button. Sample Collection and Pretreatment Remove flocked swab from transport tube. Add two (2) volumes of Gastro sample buffer to the transport tube by lifting the bottletop dispenser top up and down twice (Figure 29). The total volume is 2.6ml. Figure 29. Dispensing with the bottletop dispenser. Note! If the swab already contains stool sample, be careful not to contaminate the dispensing head of the bottletop dispenser and proceed directly to the step 3. Safety! Wear sufficient protective clothing and gloves when handling stool samples. Safety!Avoidspillinganysolutiononbareskin,eyes,ormucousmembranes. If any solution spills on the skinoreyes, wash with plenty of water and consult a doctor if necessary. Take the User's manual and SDSs withyou.

Dip the dry flocked swab into the stool and move it rigorously for 5–10 seconds (Figure 30).

Figure 30. Optimum amount of stool in the swab.

Note! Typically, the stool samples that are tested for the presence of gastrointestinal pathogens should take the shape of a container. If the sample is not watery diarrhoea swirl the swab in 4 different spots of the firm stool in order to have a representative sample.

Insert the swab with sample to the transport tube with Gastro sample buffer and close. Vortex the transport tube for 10-15 seconds to release the sample from the swab into the sample solution.

Note! Mixing that does not last long enough leads to an incomplete release of the sample from the swab and thus less sensitive test results.

in protocols.io 40 08/28/2020

novethesv gure 32).	Assembly of the wabfromthetra	e filtration unit nsporttube.Tr	ansferthesupe f solid material	if such has forr	mple(appr.2. ned by settlin	3ml) with a	a Pasteur pipette tively, connect the ing blocked by th	e syringe to the
	the amount of	nple to the syr coved from the f sample and I Pasteur pipet	inge. etransport tubereduces the pos te can be done i	sibility of conta	minating the n this way th	workstatio	ne pressed to drai on. t sample volume i	
e! When t maximize e! Sample		the pellet and						
e! When t maximize e! Sample d it is less i	likely to disturb	eandfilterthes		riPOC®Sample	ube.Thesolu	tion level s	hould meet the 1	.3 ml minimum

**Figure 34.** Filtration and minimum volume mark in the filtration unit rack.

Safety!Incaseoffoamformingontopoffiltratedsample,stopthefilteringassoonastheminimumvolumemarkis met. If the volume mark is not met, wait for the foam to settle and continue filtration carefully in order to prevent foam extruding from the sample tube through thecap.

Safety! After filtering, the piston can be lifted upwards to avoid contaminating the sample tube or workspace with drops leaking from the filter.

Remove the filtration unit carefully from the rack and detach the mariPOC  $\! ^{(\!n\!)}$  Sampletube.

Inserting Sample into Analyser

When the sample hatch's LED lightisgreen, the analyser is ready for a new sample. Open the sample hatch, remove the old sample tubes, and insert a new sample tube into the rack. The patient information on the bar code label should face the user (Figure 35) so that the analyser is able to read the bar code from behind. The analyser automatically starts processing the sample after the sample hatch is closed. The hatch becomes locked for few minutes per sample while dispensing. Already dispensed samples can be removed before the analysis results are ready. If required, samples can be stored according to instructions in chapter "7.3.2 Storage of Samples".

Figure 35. Proper orientation of the sample tubes in the sample tube rack.

Note! In most cases the sample hatch locks immediately after the hatch is closed. If, however, the analyser is in the process of measuring a sample, there can be a delay of about 30 seconds before the hatch locks.

Note! The sample tube rack can hold 1–6 sample tubes at a time. Old samples that have been already processed do not need to be removed each time the sample hatch is opened. However, the measuring program notifies that position of the sample tube rack where there already is a dispensed sample. Position number 1 is on the left edge of the rack.

## 7.3.6Reading and Reporting of the Results

The test reactions are automatically measured at one or two time points (<u>Table 20</u>) unless the preliminary time point has been omitted. At the preliminary results, the test identifies and reports strong and moderately positive samples. At the final results, the test identifies and reports low positive samples and negative test results. The result is reported with a positive (+) or negative (-) symbol.

For *S. pneumoniae* a positive result is reported semi-quantitatively as + (very low), ++ (low), +++ (medium), or ++++ (high). In the Pharyn test, group A streptococci positive result is reported semi-quantitatively as + (very low), ++ (low), or +++ (high) (see chapter "6 Test Performance"; Table 12). Optionally, reporting of + (very low) can be selected out when the test system is installed. The sensitivity of the Quick StrepA test and the preliminary result phase of group A streptococci test in the Pharyn test correspond approximately standard culture.

A red exclamation mark (!) next to the negative result in the column is indicating that a positive preliminary result has changed into a negative final result. A sound signal is played from the

computerwhenpreliminaryresultsorQuicktestresultsbecomeavailable. The sound can be muted from computer sound settings. Additional quantitative information (see instructions from **Table 22**) about the pathogen levels in

the sample can be provided next to the qualitative result in column  $\psi_0$  psi in the measuring program.

 ${\it \Psi} feature is optional. Samples obtained from mucosa are by their nature semi-quantitative and are$ 

subjecttovariabilityinsampling. However, insomecases the result quantification may still be useful in clinical practice. If reporting of  $\Psi$  values is in use, the preliminary phase identifies strong and moderately positive samples and reports them with a positive (+) symbol or with a borderline (+/-) symbol incase the assay signal is slightly below the cutoff. The final result is reported with a positive (+), borderline (+/-) or negative (-) symbol. Borderline result (+/-) should always be considered by default as negative unless result interpretation is used (see **Table 22**). For S pneumoniae the borderline (+/-) result is reported only with the preliminary result. For group A streptococci, Gastro and CDI tests borderline (+/-) results are not reported. Qualitative reporting of the results is summarized in **Table 20**.

Table 20. Qualitative result reporting.

Test	Preliminary results	Final results
Respi+ or Respi test viruses	20 min: (+/-,) +	2 h: -, (+/-,) +
Respi+ or Respi test S. pneumoniae	20 min: (+/-,) +, ++, +++, ++++	2 h: -, +, ++, +++, ++++
SARS-CoV-2 test	20 min: +	95 min: -, +
Quick Flu+ or Quick Flu/RSV test		20 min: -, +
Pharyn test adenovirus	15 min: (+/-,) +	55 min: -, (+/-,) +
Pharyn test group A streptococci	15 min: +++	55 min: -, (+,) ++, +++
Quick StrepA test		15 min: -, +
Gastro test	20 min: +	2 h: -, +

CDI test 20 min: + 2 h:-, +

In the mariPOC® CDI test, GDH and Toxin A/B test results form together the result for presence or absence of CDI ( $\underline{Table}$ 

**21**).GDHpositivityindicatesthepresenceof *C. difficile* bacteriainthesample. Simultaneous Toxin A/B positivity indicates the presence of *C. difficile* toxins causing the disease.

Table 21. Interpretation of the results in CDI test.

GDH test	Toxin A/B	Interpretation of the results
	test	
		C. difficile or its toxins A and/or B are not present in the sample. The
-	-	disease
		is very unlikely caused by <i>C.</i>
		difficile.
		Toxins A and/or B
+	+	producing <i>C. difficile</i> is present
		in the sample. The disease is likely caused by <i>C. difficile.</i>
		Non-toxigenic <i>C. difficile</i> strain is present in the sample
		or the amount
+	-	of produced toxins A and/or B is below
		the detection limit
		of the assay.
		The disease is unlikely caused by <i>C. difficile</i> .
		Optionally, molecular testing of toxin
		gene (e.g., PCR) or toxigenic culture can be used to determine the
		toxigenicity of the <i>C. difficile</i> strain.
		Invalid result. The sample
		should be reanalysed from the naïve stool sample. If the results
-	+	persist
		after retesting, consider using other methods to confirm the results.
		In rare cases, the infection may be caused by
		highly pathogenic <i>C. sordellii</i>
		(see chapters 6.2 and 10.3).

**Table 22.** Qualitative analysis results and their interpretation using additional quantitative information ( $\Psi$ , psi) combined with clinical evidence.

Result	Consider as	Situation and/or prerequisite
		The analysis signal is
-	Negative (-)	well below the cut off value of the test. No $\Psi$ (psi) value is reported.
		The analysis signal is
+/-	Negative (-)	slightly below the cut off value of the test and there is no other
		evidence
		to support the positivity.
		The analysis signal is slightly
		below the cut off value
+/-	Positive (+)	of the test but the $\Psi$ (psi) value which describes
		probability (%) of an analytically true positive finding is high and
		there is
		significant other clinical, laboratory and/or
		epidemiological
		information supporting the change of the default value (-).

		The analysis signal is above the cut off value.
+	Positive (+)	The $\Psi$ (psi) value is a signal
		multiple to cut off.

Quantification for the positive (+) and border line (+/-) results is presented in different units because the probability of a true positive result around the cut off changes non-linearly.

Analysis result with a borderline symbol (+/-) should be reported by default as negative to ensure high specificity. In case the user has other significant evidence, such as other laboratory, epidemiological, and/or clinical information that strongly supports the decision to report the result as positive, the negative (-) default result may be considered to be changed to positive (+). Depending on the clinical need, samples with +/- result may be confirmed with an amplification

basedmethodtoruleinthediagnosticresultorthepatientmayberesampledafter 12–24 hours in case the infection has just started and the microbial loads are still verylow.

From quantitative value (a signal multiple to cut off) of a positive analysis result, the user may

evaluate the accuracy of a positive finding incase of epidemiological situation, other laboratory test results, and/or clinical findings do not match. The user should take into account that the preset cut offs have been set so that the specificity of the assay (Table 11, Table 13 and Table 16) is very high when using the default reporting. Depending on the method, cut offs may be different in preliminary and final result reporting phases. Therefore, i) sometimes (with certain antigen concentrations) the  $\Psi$ (psi) value obtained in preliminary phase can be higher than the psi value obtained in the final phase, and ii)  $\Psi$ (psi) values obtained in preliminary and final phases cannot always be compared quantitatively.

The sensitivity and specificity stated by the manufacturer are derived from the default positive and negativeresults, which are based on the present cutoffs. The default results should only be changed upon joint decision of the laboratory and medical doctor responsible of the patient. Such decision shall be based on other significant evidence, such as other laboratory, epidemiological, and/or clinical information to increase the accuracy of the test result. Otherwise accuracy will suffer. The "Test status" field for each patient reports the status of the analysis (see chapter "7.2 mari POC® Software (Arc Diagnoser™ Measuring Program)"; Table 18). The selected patient information line is highlighted in blue and a line in bold letters indicates that the results have not been looked at. The patient information line remains bold for 3 seconds after its selection.

Thetestsystemincludesinternal quality control of results, i.e. autoverification, which estimates the reliability of the measurement and technical success of the analysis. When the measurement is unsuccessful, the test result is not stated. Instead, in such cases "Failed" appears in the result field and the test status in question is marked red in the patient information list. In that case an expansion of the old sample can be reanalysed (see chapter 10.3). Interfering matrix substances may rarely give falsely high fluorescent signals for negative samples despite the implemented resultant overification.

The test results of a single sample may be printed with the user's printer if necessary using the "Print" button. Report creation popup window (Figure 36) offers more possibilities for the result

 $reporting: Epidemiological report, Tests day by day and mari POC results (summary reports). The test types, pathogens or analytes and their abbreviations used in summary reports are explained in {\bf Table}$ 

23. Reportcreationisaccessed from the Moreoption spull-downmenuby selecting Reports. Select the report type and then start and end dates if applicable. The report creation will take some time.

When completed, the selected report will be shown automatically in the web browser. The report in the web browser can be saved or printed with the user's printer.

Figure 36. Report creation pop-up window.

 Table 23. The test types, pathogens and their abbreviations used in summary reports.

Test type	Pathogen or analyte	Abbreviation
Respi+ or Respi test	Influenza A virus	IAV
Influenza B virus	IBV	

Respiratory syncytial (RS) virus	RSV	
Human metapneumovirus	hMPV	
Parainfluenza virus 1	PIV1	
Parainfluenza virus 2	PIV2	
Parainfluenza virus 3	PIV3	
Human coronavirus 0C43	hCoV	
SARS coronavirus 2	SARSCoV	
Human bocavirus	hBoV	
Adenovirus	AdV	
S.	Pnc	
pneumoniae		
Quick Flu+ or	Influenza A virus	IAVQ
Quick Flu/RSV test		
Influenza B virus	IBVQ	
Respiratory syncytial (RS) virus	RSVQ	
SARS coronavirus 2	SARSCoVQ	
SARS-CoV-2 test	SARS coronavirus 2	SARSCoVs
Pharyn test	Adenovirus	AdVp
Group A streptococci	StrAW	
Quick StrepA test	Group A streptococci	StrAQ
Gastro test	Norovirus GII.4	NoVGII
Norovirus GI	NoVGI	
Rotavirus	RoV	
Adenovirus	AdVg	
Campylobacter spp.	Camp	
CDI test	C. difficile	GDH
	GDH	
C. difficile	ToxAB	
Toxin A/B		

"Epidemiological report" is automatically created for 6 month time period from the report creating dateandconsistsofresultsobtainedfromtheRespi+orRespitest(Figures1-4)andtheGastrotest (Figures 5-7). Figure 1 of the report is the weekly proportion (%) of positive samples from all tested Respi+ or Respi tests. The large variation between consecutive weeks may be due to small number of analysed samples. The intensity of epidemiological situation can be evaluated by comparing the graph with the number of weekly positive findings in report's Figures 2 and 3. In case of multiple positive findings are obtained from the same sample, each finding is taken into account. In Figure 2, the positive findings of influenza A virus (IAV), influenza B virus (IBV) and respiratory syncytial virus (RSV), are shown. Other viruses of the Respi+ or Respi test are grouped together. In Figure 3 the other viruses (grouped in Figure 2; adenovirus (AdV), SARS coronavirus 2 (SARSCoV) or human bocavirus (hBoV), human coronavirus OC43 (hCoV), human metapneumovirus (hMPV), parainfluenza virus 1 (PIV1), parainfluenza virus 2 (PIV2) and parainfluenza virus 3 (PIV3)), and S. pneumoniae (Pnc) are shown. In report's Figure 4 the proportion of positive preliminary results of the Respi+ or Respi test compared to the final positive results is presented. During the epidemiological season over 50% (typically 60-80%) of virus positive samples are, on average, positive at the preliminary phase. However, this requires that the sample collection has been timed correctly and performed according to the instructions provided by the manufacturer. If the proportion of positive results in the preliminary reporting phase is continuously lower than 50%, it is recommended that the sample collection routines, including sampling and time from the on set of symptoms, should be paid attention to. Figure 5 of the report is the weekly proportion (%) of positive samples from all tested gastro tests. The large variation between consecutive weeks may be due to small number of analysed samples. The intensity of epidemiological situation can be evaluated by comparing the graph with the number of weekly positive findings in report's Figure 6. In case of multiplepositivefindingsareobtainedfromthesamesample,eachfindingistakenintoaccount.In report's Figure 7 the proportion of positive preliminary results compared to the final positive results of the Gastro test is presented. "Tests daybyday" can be created for any times pan by freely selecting the start and end dates. The  $report consists of the following tables: successful tests, failed tests and customer support tests. The {\it test} is a successful test of the {\it test} is a su$ dailytestamountsaredividedbasedonthetestorcontrol types. The sum of dailytests is shown in the green column. The sum of tests per test type is shown in the greenrow.

"mariPOCresults" is a summary report of all performed tests including the controls. It can be created for any times pan by freely selecting the start and end dates. Positive findings and pathogen specific testswithfailedand/orchangedtestresults(betweenpreliminaryandfinalresultphases) are listed in separate columns. The final column "Test plate" provides fully traceable information of the test plate used for sample analysis. The information includes test plate's name and its REF/Lot/Serial number. The report is available also in the computer's desktop (mariPOC.csv) and can be processed in a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation in First name, Last name and ID code fields are a spread sheet application (e.g. Excel). In formation (e.g. Excel) and (e.g. Excel). In formation (e.g. Excel) and (e.g. Excel) are a spread sheet application (e.g. Excel). In formation (e.g. Excel) are a spread sheet application (e.g. Excel) and (e.g. Excel) are a spread sheet application (e.g. Excel) and (e.g. Excel) are a spread sheet application (e.g. Excel) are a spread sheet application (e.g. Excel) and (e.g. Excel) are a spread sheet application (e.g. Excel) are a spread sheet application (e.g. Excel) and (e.g. Excel) are a spread sheet application (e.g. Excel) are a spread sheet application (e.g. Excel) and (e.g. Excel) are a spread sheet application (erepeated as such. Note that a new report will automatically replace the previous one on the desktop.7.4ControlSamples The functioning and the use of the test system are also monitored by a weekly analysis of the multianalytecontrolsamplesprovidedbythemanufacturer(positiveandnegative). Controlsamples arenotusedtocalibratethesystem. One controls ample foil bagin cludes both positive and negative control samples dried in factory bar coded sample tubes. One positive control sample includes all analytes for the provided test plate type. The measuring program gives an automatic pop-up reminderwhenoneweekhaspassedsincethelastrunofcontrolsamplesforthecorrespondingtest plate type. The reminder includes instructions on handling a control sample (Figure 37). If the reminder has been closed without analysing the control samples, it will appear again until both controls arerun. Figure 37. Control sample reminder. Note! Control samples are test plate specific. When measuring program gives an automated pop-up reminder, please check the test plate type and analyse the correct set of control samples (see <u>Table 2</u>). Analysing the Control Samples: a. Open the control samples foil bag (including both the positive and the negative control sample tubes). Remove the caps of the control sample tubes. Add 1.3 ml of test specific sample buffer toeachtubebyliftingthebottletopdispensertopupanddownonce(Figure 38). Becarefulthat thepositivecontroldoesnotcontaminatethedispensinghead. Replacethecapsontheoriginal sample tubes. Be careful that the caps do not get mixed. The pink cap belongs to the positive control sample and the colourless cap to the negative controlsample. Figure 38. Adding the test specific sample buffer to the positive control sample tube. Safety!Avoidtouchingthedispensingheadwiththecontroltubeorspillinganysolutiononbareskin,eyes,ormucous membranes (see the cleaning instructions for the dispensing head in chapter 10.3). If any solution spills on the skin or eyes, wash with plenty of water and consult a doctor if necessary. Take the User's manual and SDSs withyou. b.Mix the control sample tubes separately with the vortex mixer for 10-15 seconds (Figure 39).  $c. Let the controls amples dissolve by leaving them to stand at room temperature for 2-10 minutes \, ( \underline{\textbf{Figure 39}} ).$ 

## Figure 39. Mixing and leaving to stand of control sample tubes.

d.Mix the control sample tubes again for 10-15 seconds with the vortex mixer.

e. Open the sample hatch, place the control sample tubes in the sample tube rack and close the sample hatch. The analyser begins to automatically process the control samples. The automatic pop-up reminder will close automatically when the control samples have been inserted to the testsystem.

Note! The dissolved control samples remain usable at room temperature for two hours.

Note! Controls prepared by other organisations than the manufacturer may not be technically suitable or optimal for the mariPOC® test system.

Safety! The positive control sample is potentially infectious so it must be handled and disposed of in the same way as clinical patient samples.

## Reporting the Results:

The results for control samples are reported automatically in the same way as for clinical patient samples. When using mariPOC® RTI combi+ or combi test plates, the control sample results will be available for the all Respi+ or Respi and Pharyn test analytes. When using mariPOC® Quick combi+ or combi test plates, the control sample results will be available for the all Quick Flu+ or Quick Flu/RSV and Quick StrepA test analytes. When using mariPOC® Gastro CDI combi test plates, the control sample results will be available for the all Gastro and CDI test analytes.

The results for control samples are always reported in two time points regardless of the test plate type in use (preliminary results at 20 minutes and final results at 2 hours). The preliminary results for SARS-CoV-2 test plate 's SARS-

2controlsamplesarereportedat20minutesandfinalresultsat95

minutes. The results of the positive control sample analytes should all be positive at the preliminary results. The negative control sample should always give negative test results at the final result,

however, at the preliminary results are not yet reported. It is recommended that the user observes the preliminary results for the control samples and reports any possible anomalies to customer support.

If the result given by the control sample is inconsistent with the control sample type (for example,

thenegativecontrolsamplegivesapositiveresult) and the analysis was technically successful (OK), appears the Test status (Preliminary or Finished) in red in the measuring program's patient information list (see chapter "10 Possible Problem Situations and Potential Solutions" in the User's manual). If no result is reported for an analyte at the final results and "Failed" appears in the autoverification field, the test in question has failed for that analyte. The other analyses for this

controls ample have been technically successful if OK appears in the other autoverification fields.

Theresults of the control samples, their trends, and the functionality of the analyser can be followed in the "Control data" window that can be accessed from the "More options" drop-down menu. If

the rear es everal divergent results seen among the results, customer supports hould be contacted.

## $7.5 Running\ Out\ of\ Tests\ and\ Changing\ the\ Test\ Plate$

Theusercanchangethetestplateatanytimebyselecting "Changetestplate" in the "Moreoptions" drop-down menu. In this case, the results for unfinished samples will not be reported and the test status is changed to Finished. Otherwise the measuring program automatically guides the process of running out of tests and changing the test plate. When new samples have been inserted into the analyser, it automatically dispenses the samples to the test plate or prompts the user to change the

testplate. If the user does not react to the measuring program's notification to change the test plate, the test system automatically continues to dispense samples after 5 minutes.

The user can monitor the number of remaining multianalyte tests from the top right corner of the measuring program. The user can monitor the valid test plates by selecting "List test plates" in the "More options" drop-down menu. In the new window, all test plates in use are listed and the test plateinsidetheanalyserishighlighted. The listing includes product, lotands erial numbers, and the number of remaining tests and days to expiry for each plate.

The test plates must be stored in a special storage rack (**Figure 40**) if taken outside the analyser. If the test plate change notification is given after all final results have been reported, the user is able to change the test plate directly through the notification window. In combi plates where tests, e.g. Respi (or Quick Flu/RSV) and Pharyn (or Quick StrepA) or Gastro and CDI, are consumed independently, it is possible to continue using the test plate even if one of the test types has been used up. If the test plate is not changed and there is not enough tests left for all inserted samples, the test system begins to dispense all possible samples, typically from left to right. Remaining samples will stay as pending until the test plate has been changed.

Figure 40. Storage rack for the test plates and its use.

Deployment and Storage of the Test Plate

a. The mariPOC® Software will automatically prompt the user when the test plate is almost full, full, or out of date. Change the test plate from a notification on screen or at any time "Change test plate" in the "More options" drop-down menu. The measuring program will notify if any results would belost.

 $b. Open the test plate hat chlocated on the front side of the analyser when the signal light is green. Move the white button to the left to release the lock and simultaneously pull the plate carriage out ({\it Figure~42}$ ). Remove the test plate from the analyser. Test plates in use must be stored in a special storage rack ({\it Figure~40}) or disposed of appropriately (see chapter "8 Cleaning and Waste).

Disposal"). The test platemust be placed directly to the storage rack and preferably in such way that the bar code faces the user.

c.Unused test plates should be stored in a refrigerator in their original foil bag. When taking out a new test plate for use, check that the test plate foil bag is undamaged. Cut the bag open with

scissors.Removethetestplatefromthefoilbaggraspingitontheedgeswiththefingers(<u>Figure 41</u>). When removing the test plate from the storage rack, push the test plate to front from the

gaponthebacksideoftherackandgraspitwiththefingersontheedges. Checkthattheplastic edges and the bottom of the test plate are undamaged. Avoid touching the bottom of the test plate. The test plate bottom should be dust free and unscratched. A test plate from a damaged bag or one that is broken or scratched must not beused.

Figure 41. Removing the test plate from the foil bag.				
		est plate from the foil bag.		

Placethetestplateatanangleintotheplatecarriage(backedgefirst, <u>Figure 42</u>). Notethatthe bar code side of the test plate faces up and the bar code label is on the right viewed from the

front.Pushtheplatecarriageallthewaybackinsideandensurethattheplatecarriageislocked. Close the test platehatch.

Figure 42. Placing the test plate in the plate carriage.

Note! When the signal light is red the test plate hatch cannot be opened.

Note! The measuring program cannot read the bar code if the test plate hatch is still open or the test plate is placed in the plate carriage against the instructions.

e. The test system will recognize each test plate individually based on the bar code. The test plate is valid for 30 days from the opening of the foil bag and its insertion into the analyser.

## 7.6 Changing and Emptying the Solution Containers

Monitoring of the consumption of the test system's Wash and System solutions and waste container capacity is based on a calculation of the dispensing volumes. The measuring program automatically and the dispensing volumes are the container of the dispension of t

prompts when a solution bottleneed sto be replaced or the waste container emptied. It is of utmost importance that this measuring program notification is followed so that the solutions consumption

levelcalculatorwillrecognizethecorrectsolutionlevels.Notfollowingthisnotificationwillresultin depletion of the Wash and/or System solution. This can cause the analysis to fail and/or result in erroneous results due to a failed wash. If the notification to empty is not followed, the waste container can become too full and overflow causing the fluid to flood inside the analyser. This may lead to analyser malfunction and contamination with potentially infectiouswaste.

Themeasuringprogramremembers the calculated solution amounts, even if the analyser has been accidentally switched of f. Accordingly, the solution amounts in the bottless hould not be changed. If needed, the Washand System solution bottles can be replaced and the waste container emptied by using the "Maintenance wizard" accessed through the "More options" drop-down menu and selecting the desired function.

a) Emptying the waste container: Always empty the waste container when notified by the

 measuringprogram.Afterthenotification, themeasuringprogramgives detailed instructions on how to empty the waste container. The waste container is located either on the left or the back of the analyser. The tube leading to the waste container is transparent and about 1 cm in diameter. When emptying the waste container, always we arrotective gloves because it contains both the System and Wash solution as well as patient samples. See safety data sheets for more information.

Detach the rapid-connect fitting coupled to the waste container by pressing the metallic coupling. Wipe off any solution potentially dripping out from the tube using disposable paper.

Because thereis risk of backflow, lift the waste container only after detaching the tube. Because the cap has an air hole, do not tilt the waste container to avoid spills. Unscrew the cap, empty the waste container and discard the contents appropriately. Avoid spilling any fluid on clothing, skin, eyes, or other surfaces. The waste container must not be autoclaved but it can be rinsed or washed with detergent. Screw the cap backon and return the waste container to the left side or back of the analyser. Couple the rapid connect fitting by pressing the mouth piece firmly against its counterpart until there is a "clicking" sound.

b) Replacing the Wash solution bottle: Always replace the Wash solution bottle (2L) when notified

by the measuring program. Following the notification, the measuring program will give detailed instructions on how to replace the Wash solution bottle. The Wash solution bottle is located on rights ideof the back of the analyser next to the

System solution bottle. The tubele ading to the Wash solution bottle is yellow is hand about 5 mm in diameter. When changing the bottle, always use protective gloves because the Wash solution is very alkaline. See safety data sheets formore information.

To facilitate work, the Wash solution bottle can be moved nearer to the table edge as far as the tubelengthallows. Remove the outer and inner caps of the new Wash solution bottle. Open the cap of the empty Wash solution bottle and lift it out of the bottle with its tube and support rack.

Becarefulnottoallowthecap(orthetubeattachedtoit)totouchanypotentiallydirtysurfaces. Lift the nearly empty bottle out, and replace it with a full Wash solution bottle. Place the cap (with its tube carefully in place) on the bottle and close the cap. The remaining Wash solution can be poured into the drain, taking into account the relevant legislation. Ensure that the label onthenewWashsolutionbottlecorrespondstothelabelonthereplacedWashsolutionbottle.

c)Replacing the System solution bottle: Always replace the System solution bottle (1 L) when notifiedbythemeasuringprogram. Afterthenotification, themeasuringprogram gives detailed instructions on how to replace the System solution bottle. The System solution bottle is located on the right side of the back of the analyser next to the Wash solution bottle. The tube leading to the Wash solution bottle is yellowish and about 5 mmindiameter. When changing the bottle, use protective gloves because the System solution contains surface-active substances and allow concentration (< 0.1%) of sodium azide. See safety data sheets for more information.

Tofacilitatework, the System solution bottle can be moved near er to the table edge as far as the tube length allows. Remove the outer and inner caps of the new System solution bottle. Open

thecapoftheemptySystemsolutionbottleandliftitoutofthebottlewithitstubeandsupport rack. Be careful not to allow the cap (or the tube attached to it) to touch any potentially dirty surfaces. Liftthenearly empty bottleout, and replace it with a full System solution bottle. Place the cap (with its tube carefully in place) on the bottle and close the cap. The remaining System solution can be poured into the drain taking into account the relevant legislation. Ensure that the label of the new System solution bottle corresponds to the label of the replaced solution bottle.

## 7.7 Creating Customer Support Report

In case of a test system malfunction, a request from customer support or for invoicing purposes a customer support report should be created. The short-cut icon for creating the report is located between print results button and "More options" drop-down menu. The measuring program gives detailed instructions on how to do it. ArcDiaReport zip-folder will be created to the computer's desktop. Transfer the ArcDiaReport from the desktop to a USB flash drive (USB ports can be found from the behind or the side of the computer). Note that the previous report will automatically be replacedbyanewoneonthedesktopbutnotontheUSBflashdrive.SendtheArcDiaReporttothe customer support as an emailattachment.

## 7.8 Switching the Analyser Off and On

Both the analyser and the measuring program must be kept switched on because of the automatic rinsing of the test system. If the test system will not be used for long period of time (i.e., more than one week), it can be shut down in a controlled manner. This is done by selecting "Shutdown analyser"fromthe Maintenancewizard", which is accessed through the "More options" drop-down menu of the mari POC Software. Follow the instructions. Remember to empty the waste container and change both the Wash and the System solution bottles with caps (and tubes) into water bottles pre-filled with deionized or distilled water. Finally, the program instructs the analyser to switch off viathepowers witchonits backpanel (topleft corner). After that, the measuring program prompts the user to click the "Finish" button. The measuring program will then close automatically. The test plate can then be changed or removed from the analyser. Next, the label printer, the computer and the analyser should also be switched off. When the test system is used again first switch on the analyser and then the computer and label printer. Open the measuring program from the short-cut icon on the desktop (Figure 43) and follow the on-screen instructions. Note that the water bottles must to be replaced with new Wash and System solution bottles. Empty and store the used water bottles until their nextuse.




Figure 43. Analyser short-cut icon.

The analyser must never be switched off without a controlled shutdown (Maintenance wizard: Shutdown analyser) unless there is a serious failure. Only then should the analyser be switched off

from the powers witch on the top left corner of the backpanel. As erious failure such as an overflow and the power such as an overflow of the power such as an overflow of the power such as a power such as

orasimilareventcoulddamagetheanalyser. If there is a serious failure, do not restart the analyser; instead contact customer support. In any other case, wait approximately for 5 seconds before switching the power on again. The mariPOC® Software will give an error notification about a connection break within 30 seconds of analyser restart. After the notification, the computer and measuring program can be closed and then reopened. The measuring program will start by double clicking the short-cut icon on the desktop (Figure 43). Note that this switch off procedure is to be used only in error situations and, accordingly, the measuring program will not usually prompt the user how to restart the analyser. Further, the solution bottles should not be replaced.

Clearing the computer and measuring program's memory, or deleting patient information, can only be done by the manufacturer or its representative.

## 8Cleaning and WasteDisposal

## Cleaning

If surfaces get contaminated with respiratory sample or test System solutions, the cover of the analyser and other surfaces can be wiped with a cloth moistened with water or a mild cleaning solution. The cover and other surfaces can be disinfected with a disposable cloth moistened with 70% ethanol or similar when needed.

If surfaces get contaminated with stool sample, wipe the visible stain with disposable paper and clean the area first with a disposable paper moistened with detergent. Then clean the area with

chlorinesolution(preferably1000ppm)becauseseveralfaecalpathogens(e.g.norovirus, *C. difficile* spores) tolerate cleaning with ethanol. For the final cleaning use water or/and 70% ethanol (or similar) to remove chlorine residues. Additionally Ultraviolet C (UV-C) light can be used.

If solution from e.g. sample tube or wash station has leaked inside the analyser, please contact the customer support. Visible stains in the analyser inside or cover can be cleaned as instructed above. This cleaning recommendation applies also to the other electric devices (e.g. vortex) unless otherwise stated in their User's manual. Liquids must not be sprayed directly inside or on the analyser or other electric devices.

Filtration unit rack, required when handling a stool sample, and test plate storage rack can be cleaned mechanically by brushing with a detergent solution. The rack can be disinfected with chlorine solution (e.g. 1000 ppm) and/or Ultraviolet C (UV-C) light. Remember to properly rinse the rackaftercleaningwithwateror/and70%ethanol(orsimilar). Pleasenote, that both rack's material does not tolerate temperatures over 60°C such as in dishwasher or autoclave.

## Waste Disposal

The plastic consumables used to carry out tests, such as used test plates, sampling swabs, swabs in transport tube, syringe, filter, Pasteur pipette, sample tubes and caps may contain infectious

materials. They must be disposed of appropriately. An unused test plate can be disposed with normal waste. The foil bag is suitable for metal recycling. The used or expired RTI or Gastro sample buffer,

SystemandWashsolutions,ExtractionsolutionBandthecontentsofthewastecontainerandwater bottles can be poured into the drain taking into account the local legislation and the precautions

mentionedintheUser's manual and safety datasheets. The Wash solution is designed to inactivate microbes. However, the waste should be considered potentially infectious and safety precautions should be followed when disposing the waste.

When disposing the used or expired Extraction solution A, take into account local legislation and the precautions for the disposal of sodium nitrite. Empty storage containers (except the waterbottles), unused plastic components, silica gel bags, and protective wraps can be disposed with normal waste or recycled according to their material. The manufacturer is responsible for the appropriate disposal of the analyser components.

## 9Remarks

The patient's clinical information must be taken into account when interpreting the results. The diagnosis of the patient's disease must always be done by a health care professional with a sufficient level of education. The function of the

test is to assist the professional making the diagnosis by providing limited information on the microbiological content of the sample. Those samples that give a negative result may be verified using gene amplification tests (e.g., PCR). This is recommended especially for critically ill patients, and it is advised that also positive results from such are verified using an independent method. Those samples that give positive test results can be further typed using, for example, gene amplification tests or immunodiagnostic tests. The methodological suitability of using a leftover sample from the mari POC ® tests ysteminan other test, and the stability of the sample, must be validated appropriately. For swab sampling, only the swabs defined in the Table 7 must be used. The nasophary ngeal aspirate and stool sample must be untreated (i.e., native or naïve). Nasophary ngeal was hample is not appreferred sample material. The results are reliable only if the sampling and pretreatment have been appropriate and the test is

usedinaccordancewiththeinstructionsgiveninthisUser's manual. Correct and careful sampling is of utmost importance for test success. Swab and aspirate sampling for the detection of viral pathogens should be done during viremia within 6 days from the onset of symptoms, preferably within5days. Nasopharyngealwashsamplingshould be done during viremia within5days from the onset of symptoms. Viral loads decrease over time and virus antigens are not usually detectable after 6 to 7 days from the onset of symptoms.

Samples should not be stored in any kind of transport or storage media or buffers. The preferred

wayofstoringthesamplesisintheirnaïveform. Transportandstoragemedia and buffers can affect adversely to the stability of the sample and the performance of the test.

The performance specifications stated by the manufacturer in terms of analytical and clinical sensitivity are valid for samples obtained using flocked swabs or by aspiration without saline. If the observed performance with nasopharyngeal wash samples does not match with the specifications of the manufacturer or the results reported in the literature, please use nasopharyngeal swabs and/or aspirates (no saline addition), which are primarily recommended by the manufacturer.

Recently administered oral rotavirus vaccine may give a positive result in the rotavirus test.

mariPOC® toxin A/B method of the CDI test cross-reacts with toxins produced by *C. sordellii*. Cross-reaction with *C. sordellii* toxins is a known property of the mariPOC® toxin A/B test and some other

commercially available  $\mathcal{C}$ . difficile to xin A/B tests. However, mariPOC  $\mathbb{G}$  GDH test does not cross-react with  $\mathcal{C}$ . sor dellii. See chapters  $\underline{6.2}$  and  $\underline{10.3}$  for more information.

mari POC \$+ measuring program is primarily intended for laboratories. Along with qualitative results, it provides quantitative information about the microbe levels in the sample (indicated in the

measuringprogram's results column  $\psi$ , psi). Mucosal samples are by their nature semi-quantitative

atbestwithrespecttomicrobialloadinthetissue. Therefore, the results are subject to variability in sampling. Optionally, reporting of  $\psi$  values can be selected out when the test system is installed.

The sensitivity and specificity stated by the manufacturer are derived from the default positive and negativeresults, which are based on the presence to the laboratory

negativeresults, which are based on the presetcut offs. The default results should only be changed upon joint decision of the laboratory and medical doctor responsible of the patient. Such decision shall be based on other significant evidence, such as other laboratory, epidemiological, and/or clinical information to increase the accuracy of the test result. Otherwise accuracy will suffer.

Analyser is basic electromagnetic equipment (class A; CISPR 11:2009, 5:3). The system is intended to be used in light-industrial locations such as laboratories.

The computer used with the mariPOC® test system should not be connected to an information network without manufacturer's authorization. The computer can be connected to a mobile network temporarily if instructed by the manufacturer or manufacturer's representative e.g. when problem situations are solved via remote access.

If more than one test system is being used in the same department, care must be taken not to mix the test plates and the sample tubes between the test systems. The analyser identifies the sample tube by its bar code label and does not allow it to be reused: i.e., the used bar codes are both analyser and measuring program-specific. A sample tube bar code created by another test system will not be recognized and thus the sample will not be analysed. Additionally, one analyser will not identify test plates partially or completely used by another analyser, so that inserting the used test plate in another analyser will with high probability give wrong results.

Themanufacturerhasdesignedthetestsystemsothatcross-contamination from one sample or test to another is rare. Carelessness in sample pretreatment can, however, lead to cross-contamination and therefore the interpretation of results must be carefully reviewed in relation to the patient information.

Each test marked as RUO is intended for research use only. Results from such tests with RUO status should not be used for clinical diagnostics. The manufacturer or its representative provides separately more information about RUO tests.

10Possible Problem Situations and Potential Solutions

10.1 When to Contact Customer Support

The test system malfunction is typically indicated with an error notification in the dialogue window.

Contactcustomersupportimmediately if the fault diagnosis and repair instructions presented in the chapters below do not result in a

functioning test system. Examples of issues requiring immediate customer supportare:

The analyser, or the measuring program, isunresponsive.

Recurrent failedresults.

Unexpected results for the controlsamples.

A flooded washing station caused, for example by a flooding waste container or a blockage in the washing station or itstube.

A bent or detached dispensingneedle.

Faulty operation of the sample tube rack, the sample hatch, the plate carriage or the test plate hatch.

Abnormal sounds.

Foreign bodies inside theanalyser.

10.2 Problems when Using the Test System

Problem: The analyser does not respond to the commands given in the measuring program. The results are not completed.

Reason for the problem	Solution / Action
The connection between the computer and the analyser is disturbed or has disconnected.	Check that the analyser power is switched on and that the Ethernet cables between the analyser and the computer are connected. Make sure the Ethernet switch is turned on. Try to close the measuring program by clicking on the cross in the top right corner of the main window. If the measuring program closes, start it again from the short-cut icon on the desktop. If the problem persists, contact customer support.

**Problem:** The bar code reader does not recognize a sample tube.

Reason for	Solution /
the problem	Action
The sample tube bar code is the wrong way round or	Rotate the sample tube so that the patient's name
is at the wrong height, or the bar code label has been	is visible through the gap in the sample tube rack and then close
attached diagonally or	the sample
crosswise, or is wrinkled.	hatch. If this does not help, double-click the patient information
	line to
	open the "Patient
	information" window and print a new bar
	code label. Insert the sample tube into the sample tube rack
	gently to
	prevent it from getting stuck.
Please note message: "Too	Re-enter the patient information and print a new
old sample tube at pos." (i.e., bar code has been printed	bar code label. The old bar code label may need to be detached.
over 24 hours ago),	Make sure
or Warning messages: "Already dispensed sample tube	that the sample
at pos." (i.e. the sample	solution has not expired
has already been dispensed) or "Unknown sample tube $$	(storage instructions are found in chapter 7.3.2). If the sample
at pos." (i.e., the bar	has
code label is not recognized.	expired, a new sample should be taken from the patient. Insert
	the sample
	tube gently into the sample tube rack to prevent it from getting
	stuck.
The operation of the bar	Contact customer support.
code reader or measuring program has slowed down or	
ended. The bar code	
reader is broken.	

**Problem:** The analyser does not accept the control samples.

Reason for	Solution /
the problem	Action
The control sample has	Make sure that the control sample expiry has not
expired or its processing in the analyser has not begun	passed. In the case that the control sample has been pending for
within two (2) hours	more than
of reading the bar code.	two (2) hours, for example due to a test plate change, the
	measuring program
	will
	automatically reject it. Repeat the test using new
	control samples.

Problem: Analyser does not accept the positive control.

Reason for	Solution /
the problem	Action
Control samples were inserted into the analyser	Analyse new control
but the positive control was rejected (notification	samples and make sure the package is for correct test plate: REF
prompted).	1104MC for
Negative control was analysed.	mariPOC® Respi+, mariPOC® Respi, mariPOC® RTI combi+,
	mariPOC® RTI combi, mariPOC®
	Quick combi+ and mariPOC® Quick combi test plates, REF
	1204SC for mariPOC®
	SARS-CoV-2 test plate, REF 1104MC or 1124MC for mariPOC®
	Pharyn test plate
	and REF 2017MC for mariPOC® Gastro, CDI and Gastro CDI
	combi test plates.
	Contact
	customer support if the problem continues.
Control samples were	Rotate the positive
inserted into the analyser but the	control tube so that the text is visible through the gap in the
positive control was rejected without a notification.	sample tube
Negative control was analysed.	rack and then close the sample hatch. Contact
	customer support if the problem continues.

**Problem:** The sample hatch will not lock.

Reason for	Solution /
the problem	Action
A measurement is in progress.	Wait 30 seconds. The sample hatch should lock
	after the measurement is finished.
The sample hatch has not been closed properly.	Open the sample hatch
	slightly and close it again. Make sure that the sample hatch is
	fully
	closed. Contact customer support if the
	problem persists.

 $\textbf{Problem:} \ \ \textbf{The System solution has run out.}$ 

Reason for	Solution /
the problem	Measure Solution / Action

The notification to change System	Change the	
solution bottle has been	System solution bottle	
ignored. The test performance may	in accordance with	
have impeded by Wash solution residues.	the "Change system solution container" instruction	
	found on the "Maintenance wizard", which	
	can be opened from the drop-down menu "More	
	options".	

**Problem:** The Wash solution has run out.

Reason for	Solution /
the problem	Measure Solution / Action
The notification to change	Change the Wash solution bottle in accordance with
Wash solution bottle has been ignored.	the "Change wash solution container" instruction found on the
Possible cross-contamination between	"Maintenance
samples.	wizard", which can be opened from the drop-down menu "More
	options".
	Interpret the results with caution.

**Problem:** The use of Extraction solutions in the Pharyn or Quick StrepA test has been forgotten.

Reason for	Solution /
the problem	Action
Sample processing contrary to the instructions.	If the Streptococcus group
	A analysis gives a negative result, this should be reported with
	caution. If
	necessary, take a new patient sample and process it in
	accordance with the
	instructions. The Extraction solutions significantly enhance the
	analytic
	sensitivity of the group A streptococci analysis.

**Problem:** There is white powder or dirt on the dispensing needle or the top surface of the washing station.

Reason for	Solution /
the problem	Action
Some solution components,	Carefully
such as salt or washing agent, have dried.	rub the material with a swab moistened with purified water.
	Avoid bending the dispensing needle. If
	this does not help, contact customer support.

**Problem:** The bar code label does not get printed.

Reason for	Solution /
the problem	Action

The label tape has run out.	Change to a new label tape cartridge. If the bar code label does not print automatically after the repair measures, double-click the patient information line to reopen the "Patient information" window. The bar code label can be printed again, but the information entered cannot be changed.
The computer is not communicating with the label printer.	Check whether the label printer power is on (indicated by a green light is on the front) and that it is connected to the computer with a cable. Turn the label printer back on again. If the bar code label does not print automatically after the repair measures, double-click the patient information line to reopen the "Patient information" window. The bar code label can be printed again, but the information entered cannot be changed.
Error notification: "Label printer does not recognize the label tape".	Switch the label printer off and turn it back on again. If this does not help, try to put the label tape cartridge back in the printer. The bar code label can be printed again by double-clicking the patient information line to open the "Patient information" window.

## 10.3Problems with Results

**Problem:** The status of the analysis (Test status) is indicated in red text. One or more analysis has failed (i.e. no result is obtained and the text "Failed" appears after the analyte in the results).

Reason for	Solution /
the problem	Action

The total sample volume is too small (pretreatment has failed); the analyser cannot aspirate enough of

the sample in the dispensing system.

# The solution level should be about halfway of the sample tube height.

Reanalyse

the sample. Re-enter the patient information and print a new bar code label.

Remove the old bar code before attaching the new one. Check that the adjusted volume in the bottletop dispenser is 1.3 ml. Make

sure that the bottletop dispenser piston is lifted to the top position.

## Throat swab

sample: Make

sure that RTI sample buffer, in

addition to Extraction solutions A and B, has been

added to the sample. If RTI

sample buffer has been forgotten, add 1.3 ml of RTI sample

buffer with the

bottletop dispenser. If there is RTI sample buffer

in the sample tube, add approximately 0.5 ml of the RTI sample buffer to the

sample tube, and vortex for 10-15 seconds.

**Nasopharyngeal swab sample:** Make sure that RTI sample buffer has been added to

the sample. If RTI sample buffer has been forgotten, add 1.3 ml of RTI sample buffer with the bottletop dispenser. If there is RTI sample buffer in the sample tube,

add approximately 0.5 ml of the RTI sample buffer to the sample tube,

and vortex for 10-15 seconds.

## **Aspirate**

sample: Sample

to be reanalysed after addition of RTI sample buffer must be vortexed for

10-15 seconds and centrifuged before

inserting it into the analyser.

**Stool sample:** For a failed stool sample repeat the sample pretreatment. Check that

the stool sample (flocked swab) was diluted into two volumes of the Gastro

sample buffer (2x 1.3 ml) and that the pretreated sample solution volume in

the Gastro sample tube is at or above the volume mark pointed in the filtration unit

rack. If there is no naïve

sample left, re- filter the pretreated sample. Before re-filtering, add Gastro sample

buffer (if needed) until the total sample volume is approximately

ml to ensure enough (1.3

ml) flow-through after

the second filtration. However, please

note that dilution may have a negative effect on the test sensitivity.

Reason for	Solution /
the problem	Action
Dispensing has failed. Difficult sample material	The sample solution may be too viscous (mucous) or
or the filter in stool sample pretreatment was faulty.	contain particular material. Reanalyse the sample. Re-enter the patient
	information and
	print a new bar code label. Remove the old
	bar code before attaching the new one.
	Throat/nasopharyngeal
	<b>swab sample:</b> Add approximately 1 ml of the RTI sample buffe to the failed sample,
	and vortex for 10-15 seconds. The solution level should be over
	2/3 of the
	sample tube height.
	Aspirate
	sample: Sample
	to be reanalysed after addition of RTI sample buffer must be
	vortexed for
	10–15 sec and centrifuged before inserting it into the analyser.
	Stool
	Sample: Check
	that the stool sample was pretreated (filtered) as instructed.  Make the
	pretreatment again from the naïve stool sample if there is sample left. If
	there is no naïve sample left, re-filter the
	pretreated sample. Before re-filtering, add Gastro
	sample buffer (if needed) until the total sample volume is
	approximately 2.3
	ml to ensure enough (1.3 ml) flow-through after the second filtration.
	However, please note that dilution may have a negative effect on
	the test
	sensitivity.
The dilution of the Pharyn	Change to a new System solution bottle immediately
or Quick StrepA test (done automatically on the test	using the
plate) has failed	Maintenance
because the System solution has run out.	wizard. The sample must be reanalysed. Re-enter the
	patient information and print a new bar code
	label. Remove the old bar code before attaching the new one.  Addition of RTI
	sample buffer to sample tube is not needed. Insert the sample
	tube into the
	sample tube rack gently to prevent it from getting stuck. Vortex
	the sample
	tube for 10-15 seconds.
	The measuring program
	calculates consumption of System solution and will not work
	correctly if a
	user changes the bottle before a notification is given by the
	measuring
	program or if a notification is ignored.
Control samples were	Analyse a new set of control samples and make the
inserted to the analyser without addition of test specific sample buffer and	pretreatment as instructed in chapter 7.4.
vortexing.	

**Problem:** Theresults give a reason to suspect that the samples are cross-contaminated. For example, a negative control sample gives a positive result or a borderline result (+/-) in two or more consecutive control runs.

Reason for	Solution /
the problem	Action
The RTI sample buffer or	Clean the outside of the
the	bottletop dispenser by wiping with 70% ethanol or similar.
dispensing head of the	Dispense 10 times into the drain to rinse the
bottletop dispenser is contaminated (cross-	dispensing head. Change to a new RTI sample buffer
contamination).	bottle and dispense 10 times into
	the drain again. If required, the bottletop dispenser can be autoclaved by
	following the manufacturer's instructions. Remember to
	recalibrate the dispenser after autoclaving.
The Gastro sample buffer	Clean the outside of the
or the dispensing head of the bottletop dispenser is	bottletop dispenser by wiping the visible stain with disposable
contaminated (cross- contamination suspicion).	paper and
	then with disposable paper moistened with detergent. Then clean the outside
	with chlorine solution (preferably 1000 ppm) because several
	faecal pathogens
	(e.g. norovirus, <i>C. difficile</i> spores)
	tolerate cleaning with ethanol. For the final cleaning use water
	or/and
	70% ethanol (or similar) to remove chlorine
	residues from the dispensing head. Dispense 10 times into the
	drain to rinse
	the dispensing head.
	Additionally, Ultraviolet C (UV-C) light or
	autoclave can be used. Remember to follow the manufacturer's
	instructions and
	recalibrate the dispenser after autoclaving. Change to a new
	Gastro sample
5.	buffer bottle and dispense 10 times into the drain.
Between samples, the	Check the procedure for cleaning the scissors.
scissors have not been adequately cleaned.	Clean the scissors carefully between samples using 70% ethanol or similar and
The Week colution has more and	then wiping them with disposable paper.
The Wash solution has run out.	Change a new Wash solution bottle immediately.  Select "Change wash solution container" from the "Maintenance
	wizard" that
	can be opened from the drop-down menu "More options".
	Interpret the results
	with caution.
	The measuring program calculates consumption of
	Wash solution and will not work correctly if a user changes the
	bottle before
	a notification is
	given by the measuring program or if a
	notification is ignored.

**Problem:** The result for a negative control sample is reported with a borderline symbol +/-.

Reason for	Solution /
the problem	Action

The analysis signal of negative samples or	Result for a negative control with a borderline	
negative controls can occasionally	symbol (+/-) should be considered by default as negative.	
be close to the cut off due to statistical		
reasons. Nevertheless, borderline result is lower than		
the clinical cut off		
set by the manufacturer for reporting of positive		
findings.		

**Problem:** The result for a positive control sample is negative.

Reason for	Solution /
the problem	Action
The test reagents or the	Make sure that the test plate or the control
control sample have been spoiled or the	sample have not been stored contrary to the instructions and that
control sample treatment instructions, for example	the control
mixing and/or settling, have not been followed.	sample pretreatment length has been in accordance with the
	instructions. The
	control sample must not be treated with the Extraction solutions
	intended for
	the Pharyn and Quick StrepA test methods. Repeat the test using
	a new control
	sample. If the negative result recurs, contact customer support.

**Problem:** 3 or more positive virus results from a single patient sample.

Reason for	Solution /
the problem	Action

HAMA (human anti-mouse antibody) response or other interfering agent causes unspecific binding in the antigen detection

reaction. There are multiple

pathogens (e.g. sewer water based illness).

Consider the results with caution and compare the results to existing clinical and epidemiological data.

Throat/nasopharyngeal swab sample: If possible,

resample the

patient.

Reanalysing the respiratory sample can reduce the amount of interference and increase the reliability of

analysis. However, there is a risk that some false positives still remain and

this complicates the use of the result in clinical decision-making.

decide to reanalyse the sample, add approximately 1 ml of the  $\ensuremath{\mathsf{RTI}}$  sample

buffer to the failed

sample, and vortex for 10-15 seconds. The solution

level should be about 2/3 of the sample tube height. Re-enter the

information and print a new bar code label. Remove the old bar code before

attaching the new one.

#### **Aspirate**

sample: Sample

to be reanalysed after addition of RTI sample buffer must be vortexed for

10–15 sec and centrifuged before inserting it into the analyser.

#### Stool

sample: Repeat

the sample pretreatment or resample the patient if possible.

Reanalysing the

stool sample after freeze-thaw treatment may reduce the amount

ot

interference and increase the reliability of analysis.

However, there is a possibility that some false positives still remain and

this complicates the use of the result in

clinical decision-making. Consider using other methods to confirm the

results. Note, however, that the

interfering agent may also affect the reliability

of other methods.

**Problem:** C. difficile GDH test gives a negative while Toxin A/B test gives a positive result.

Reason for	Solution /
the problem	Action

C. difficile GDH negative but Toxin A/B positive result Negative GDH might have been caused by but positive toxin cross-reaction with C. sordellii toxins. A/B result should be considered invalid by default. Make the pretreatment again from the naïve stool sample if there is sample left. If there is no naïve sample left, re-filter the pretreated sample. Before re-filtering, add Gastro sample buffer (if needed) until the total sample volume is approximately 2.3 ml to ensure enough (1.3 ml) flow-through after the second filtration. However, please note that dilution may have a significant effect on the test sensitivity. Cross-reaction with *C. sordellii* toxins is a known property of the mariPOC® Toxin A/B test and some other commercially available difficile toxin tests. C. sordellii toxins are homologous to toxins produced by C. difficile. C. sordellii is a pathogen with clinical relevance. Therefore, if the results persist after reanalysis, C. sordellii should be suspected and further tested with other methods.

Problem: Not enough sample solution in the Gastro/CDI sample tube after filtration.

Reason for	Solution /		
the problem	Action		
Too little Gastro sample	Make the pretreatment		
buffer was used to suspend the sample, filter was	again from the naïve stool sample if there is sample left. Pay		
blocked, there was too much of stool	attention to		
in the swab or the stool was too firm.	the Gastro sample buffer amount. If the sample volume is still		
	not sufficient		
	(≥1.3 ml) after filtration, combine the two pretreated samples.		
	If there is no naïve		
	sample left, re-filter the pretreated sample. Add Gastro sample		
	buffer until		
	the total sample volume is approximately 2.3 ml to ensure enough		
	(1.3 ml)		
	flow-through after the second filtration. However, please note		
	that dilution		
	may have a significant effect on the test sensitivity.		

Problem: There is a red exclamation mark (!) next to the negative result.

Reason for	Solution /
the problem	Action
A positive preliminary	Report the result as a
result was	negative finding. The final result is more specific than the rapid
changed into a negative	preliminary result.
result in the final analysis.	
Incorrect positive	
preliminary result may be	
due to an interfering substance present in the sample.	
The substance is most often inactivated during the	
incubation.	

#### 11 Test System Technical Data

Analyser

Dimensions: 41 x 50 x 41cm

Weight: 32kg

Serial and type numbers: see the type plate located on the backside theanalyser

Voltage: mains electricity supply 100-230 V, 50-60Hz

Input power: 25W

Accessories (application dependent): mariPOC® Software (ArcDiagnoser<sup>TM</sup> measuring program), Ethernet switch and cables, power supply, computer with display, keyboard, mouse, label printer, label tape cartridge, bottletop dispenser with stand, vortex mixer, sample tube rack, sample tube box, sample tube cap box, filtration unit rack, test plate storage rack, User's manual, rapid instructions and safety datasheets

Plastic consumables (application dependent): sample tube, sample tube cap, swab in transport tube, syringe, filter and Pasteurpipette

**Chemical Composition** 

Test plates: pathogen specific biochemical reagents (immunoglobulins) and buffercomponents (under 0.1% NaN3) dried on a test plate and coveredhermetically

Negative control samples: no notifiable chemical components

Positive controls amples: in activated and possibly infectious viral and bacterial preparations, recombinant proteins and buffer components (under 0.1% NaN3)

RTI sample buffer: buffer components, surface active agents, bovine serum albumin (BSA) and NaN3 (under0.1%)

 $Gastrosample buffer: buffer components, surface active agents, bovine serum albumin (BSA) \ and \ NaN3 \ (under 0.1\%)$ 

Wash solution: alkaline (pH 12) non-foaming washsolution

System solution: buffer components, surface active agents and NaN3 (under0.1%)

ExtractionsolutionA:sodiumnitrite(Warning:AcuteTox.4,Harmfulifswallowed.European Regulation (EC) No1272/2008)

Extraction solution B: buffer components, acidicsolution

For more information about chemical composition, H-statements and R-phrases, please see the safety data sheets (SDS).

12 Symbols Description	

Figure 44. Description of the symbols in the User's manual and on labels.

## 13Warranty

The mariPOC® test system has a 12 month warranty. The warranty begins when installation is accepted by the User. The warranty does not cover damage caused by use contrary to the Manufacturer's instructions.

The warranty on the test's consumables only covers defects in manufacture process and damage during transportation. The Manufacturer guarantees the reliability of the tests until their use-by

date, which is stated on package. The User is responsible for storing each component in the condition defined in the User's manual. Repairs, adjustments and other changes to the test system may only be performed by persons authorized by ArcDia International Oy Ltd. If you suspect that the test system is faulty contact the aforementioned entities immediately.

## 14Literature

Prospective Evaluation of the mariPOC® Test for the Detection of *Clostridioides difficile* GDH and Toxins A/B. Savolainen R, et al. J Clin Microbiol. (2019) 58(4). DOI: 10.1128/JCM.01872-19.

Evaluation of a Gastrointestinal Pathogen Panel Immunoassay in Stool Testing of Patients with Suspected *Clostridioides* (*Clostridium*) difficile Infection. Krutova M, et al. J Clin Microbiol. (2019) 57(10). DOI: 10.1128/JCM.00710-19.

Prospective evaluation of a new mari POC respites twith improved sensitivity for influenza Avirus. Thomas E, et al. 29 th European Congress of Clinical Microbiology and Infectious Diseases 2019, Amsterdam, the Netherlands. Abstract #2977 and poster #P0114.

 $\label{lem:microbial identification from feces and urine in one step by two-photon excitation as say technique. Koskinen, JM, et al.\ J\ Immunol\ Methods.\ (2018) 460:113-118.$ 

Rapid detection and monitoring of human coronavirus infections. Bruning AH, et al. New Microbes New Infect. (2018) 24:52-55.

mariCloud<sup>TM</sup>on-lineserviceforreal-timeandglobalepidemiologicalsurveillanceofacuteinfections.KoskinenJO,etal. International scientific WHO conference "Trends in influenza research" 2017, St. Petersburg, Russia. Plenary lecture. Abstract p. 26-27.

NewQuickStrepAtestofautomatedmariPOC®systemprovidesculturesensitivityin15minutes. Antikainen P, etal. 34th annual meeting of NSCMID 2017, Tórshavn, Faroe Islands, Denmark. Abstract and poster#PP02.36.

Novel automated mariPOC® test for Clostridium difficile infection realises the updated ESCMID diagnostic guideline. Mäkilä J, et al. 27th European Congress of Clinical Microbiology and Infectious Diseases 2017, Vienna, Austria. Abstract #984 and poster #FV0169

Automated mari POC @platformen ableshighly sensitive and rapid antigen detection and subtyping of influenza viruses.

AntikainenP,etal.InternationalscientificWHOconference"TrendsinInfluenzaResearch 2017",St.Petersburg,Russia. Abstract 023, p. 71-73 and oral presentation.

ComprehensiveReal-TimeEpidemiologicalDatafromRespiratoryInfectionsinFinlandBetween2010and2014Obtained from an Automated and Multianalyte mariPOC® Respiratory Pathogen Test. Gunell M, et al. Eur J Clin Microbiol Infect Dis. (2016)35(3):405-13

DetectionandmonitoringofHumanBocavirus1infectionbyanewrapidantigentest.BruningAH,etal.NewMicrobes New Infect. (2016)11:17-9.

Comparison of mariPOC® gastro, a new multianalyte test for acute gastroenteritis, and five norovirus lateral flow tests. Koskinen JM, et al. 26th European Congress of Clinical Microbiology and Infectious Diseases 2016, Amsterdam, the Netherlands. Abstract and poster #EVLB60.

European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Crobach MJT, et al. Clin Microbiol Infect. (2016) Suppl 4S:63-81.

Analyticalperformanceoftheautomatedmultianalytepoint-of-caremariPOC®forthedetectionofrespiratoryviruses. Sanbonmatsu-Gámez S, et al. Diagn Microbiol Infect Dis. (2015)83(3):252-256.

Detection of Group A Streptococcus from Pharyngeal Swab Samples by Bacterial Culture is Challenged by a Novel mariPOC Point-of-Care Test. Vakkila J, et al. J Clin Microbiol. (2015) 53(7):2079-83.

Evaluation of the Automated Multianalyte Point-of-Care mariPOC® Test for the Detection of Influenza A Virus and Respiratory Syncytial Virus. Tuuminen T, et al. J. Med. Virol. (2013) 85(9):1598-1601.

Identification of Respiratory Viruses with a Novel Point-of-Care Multianalyte Antigen Detection Test in Children with Acute Respiratory Tract Infection. Ivaska L, et al. J Clin Virol. (2013) 57(2):136-140.

NoCross-ReactionsDetectedbymariPOC®GroupAStreptococciAntigenTestwithStreptococcusanginosus.Antikainen P, et al. GAS Infections 2013, Rome, Italy. Abstract andposter.

Performance Evaluation of Multianalyte mariPOC® Respiratory Infection Test for Adenovirus Types 1-8, 14, 19 and 21. KoskinenJO,etal.22ndEuropeanCongressofClinicalMicrobiologyandInfectiousDiseases2012,London,UK.Abstract.

Rapid Method for Detection of Influenza A and B Virus Antigens by Use of a Two-Photon Excitation Assay Technique and Dry-Chemistry Reagents. Koskinen JO, et al. J Clin Microbiol. (2007) 45(11): 3581-8.

A New Microvolume Technique for Bioaffinity Assays Using Two-Photon Excitation. Hänninen P, et al. Nat Biotechnol. (2000) 18(5):548-50.

# 15 Manufacturer's Contact Details

 $mari POC \$, Arc Diagnoser^{TM} \ and \ Arc Dia^{TM} \ are \ trademarks \ of \ Arc Dia \ International \ Oy \ Ltd.$ 

ArcDia International Oy Ltd Lemminkäisenkatu 32 20520 Turku, Finland <a href="mailto:www.arcdia.comsupport@arcdia.com">www.arcdia.comsupport@arcdia.com</a>

FOR IN VITRO DIAGNOSTICS		
Latest User's manual update: 2020-05		